<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="pmc-domain-id">1754</journal-id><journal-id journal-id-type="pmc-domain">frontimmu</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC5934487</article-id><article-id pub-id-type="pmcid-ver">PMC5934487.1</article-id><article-id pub-id-type="pmcaid">5934487</article-id><article-id pub-id-type="pmcaiid">5934487</article-id><article-id pub-id-type="pmid">29755472</article-id><article-id pub-id-type="doi">10.3389/fimmu.2018.00897</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>The Elusive Anti-<italic toggle="yes">Candida</italic> Vaccine: Lessons From the Past and Opportunities for the Future</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Tso</surname><given-names initials="GHW">Gloria Hoi Wan</given-names></name><xref ref-type="author-notes" rid="fn002"><sup>&#8224;</sup></xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://frontiersin.org/people/u/397654"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Reales-Calderon</surname><given-names initials="JA">Jose Antonio</given-names></name><xref ref-type="author-notes" rid="fn002"><sup>&#8224;</sup></xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://frontiersin.org/people/u/219313"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pavelka</surname><given-names initials="N">Norman</given-names></name><xref ref-type="corresp" rid="fn001">*</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://frontiersin.org/people/u/35352"/></contrib></contrib-group><aff><institution>Singapore Immunology Network (SIgN), Agency of Science, Technology and Research (A*STAR)</institution>, <addr-line>Singapore</addr-line>, <country>Singapore</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Steven Templeton, Indiana University School of Medicine-Terre Haute, United States</p></fn><fn fn-type="edited-by"><p>Reviewed by: Jeniel E. Nett, University of Wisconsin-Madison, United States; Rebecca Drummond, National Institutes of Health (NIH), United States</p></fn><corresp id="fn001">*Correspondence: Norman Pavelka, <email>norman_pavelka@immunol.a-star.edu.sg</email></corresp><fn fn-type="other" id="fn002"><p><sup>&#8224;</sup>These authors have contributed equally as first authors.</p></fn><fn fn-type="other" id="fn003"><p>Specialty section: This article was submitted to Microbial Immunology, a section of the journal Frontiers in Immunology</p></fn></author-notes><pub-date pub-type="epub"><day>27</day><month>4</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>9</volume><issue-id pub-id-type="pmc-issue-id">305241</issue-id><elocation-id>897</elocation-id><history><date date-type="received"><day>15</day><month>2</month><year>2018</year></date><date date-type="accepted"><day>11</day><month>4</month><year>2018</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>01</month><year>2018</year></date></event><event event-type="pmc-live"><date><day>11</day><month>05</month><year>2018</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-08-16 20:25:20.747"><day>16</day><month>08</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2018 Tso, Reales-Calderon and Pavelka.</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Tso, Reales-Calderon and Pavelka</copyright-holder><license xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fimmu-09-00897.pdf"/><abstract><p>Candidemia is a bloodstream fungal infection caused by <italic toggle="yes">Candida</italic> species and is most commonly observed in hospitalized patients. Even with proper antifungal drug treatment, mortality rates remain high at 40&#8211;50%. Therefore, prophylactic or preemptive antifungal medications are currently recommended in order to prevent infections in high-risk patients. Moreover, the majority of women experience at least one episode of vulvovaginal candidiasis (VVC) throughout their lifetime and many of them suffer from recurrent VVC (RVVC) with frequent relapses for the rest of their lives. While there currently exists no definitive cure, the only available treatment for RVVC is again represented by antifungal drug therapy. However, due to the limited number of existing antifungal drugs, their associated side effects and the increasing occurrence of drug resistance, other approaches are greatly needed. An obvious prevention measure for candidemia or RVVC relapse would be to immunize at-risk patients with a vaccine effective against <italic toggle="yes">Candida</italic> infections. In spite of the advanced and proven techniques successfully applied to the development of antibacterial or antiviral vaccines, however, no antifungal vaccine is still available on the market. In this review, we first summarize various efforts to date in the development of anti-<italic toggle="yes">Candida</italic> vaccines, highlighting advantages and disadvantages of each strategy. We next unfold and discuss general hurdles encountered along these efforts, such as the existence of large genomic variation and phenotypic plasticity across <italic toggle="yes">Candida</italic> strains and species, and the difficulty in mounting protective immune responses in immunocompromised or immunosuppressed patients. Lastly, we review the concept of &#8220;trained immunity&#8221; and discuss how induction of this rapid and nonspecific immune response may potentially open new and alternative preventive strategies against opportunistic infections by <italic toggle="yes">Candida</italic> species and potentially other pathogens.</p></abstract><kwd-group><kwd><italic toggle="yes">Candida</italic></kwd><kwd>candidemia</kwd><kwd>candidiasis</kwd><kwd>vaccine</kwd><kwd>trained immunity</kwd><kwd>opportunistic infections</kwd><kwd>immunocompromised patients</kwd></kwd-group><funding-group><award-group><funding-source id="cn01">A*STAR Investigatorship</funding-source><award-id rid="cn01">JCO/1437a00117</award-id></award-group><award-group><funding-source id="cn02">Signe ja Ane Gyllenbergin S&#228;&#228;ti&#246;</funding-source></award-group></funding-group><counts><fig-count count="2"/><table-count count="1"/><equation-count count="0"/><ref-count count="137"/><page-count count="13"/><word-count count="11499"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="introduction" id="S1"><title>Introduction</title><p>Due to advances in medicine and surgery, over the past century there has been a rising population of immunocompromised patients, which are at an elevated risk to suffer from opportunistic infections (<xref rid="B1" ref-type="bibr">1</xref>, &#8201;<xref rid="B2" ref-type="bibr">2</xref>). While hospital-acquired fungal infections are less frequent than bacterial ones, they disproportionately account for higher mortality rates, longer hospitalization times and increased healthcare costs (<xref rid="B3" ref-type="bibr">3</xref>). Risk factors for fungal infections are very broad and nonspecific, and they include chronic respiratory disease, cancer, HIV infection, organ transplantation, neutropenia, presence of central venous catheters, prolonged hospital stay, administration of total parenteral nutrition, exposure to invasive procedures, chemotherapy, hemodialysis, gastric acid suppression, and use of broad-spectrum antibiotics (<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>). Candidiasis (caused by <italic toggle="yes">Candida</italic> species) is the most common opportunistic fungal infection and the fourth most common nosocomial bloodstream infection (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>). Despite the best available standards of care, the incidence of candidemia, a sign of invasive or systemic candidiasis, is on the rise in the US (<xref rid="B8" ref-type="bibr">8</xref>) and mortality rates often exceed 50% despite use of antifungal drugs (<xref rid="B9" ref-type="bibr">9</xref>). This is especially true in intensive care units and in immunocompromised patients, where <italic toggle="yes">Candida</italic> bloodstream infections are estimated to strike ~400,000 patients a year, with an associated mortality of 46&#8211;75% (<xref rid="B10" ref-type="bibr">10</xref>). For all these reasons, and because the hospitalization and treatment cost of these patients is very high (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B11" ref-type="bibr">11</xref>), CDC guidelines recommend prophylactic or preemptive antifungal treatment in patients considered at high risk of candidemia (<xref rid="B12" ref-type="bibr">12</xref>).</p><p>Mucosal fungal infections, though almost never life-threatening, are much more common than invasive ones and can be associated with high morbidity, socioeconomic impact, and low quality of life. The most common infection sites are the oral cavity and the genitourinary tract (<xref rid="B13" ref-type="bibr">13</xref>). Vulvovaginal candidiasis (VVC) is the most common mucosal fungal infection, with different studies estimating that 50&#8211;70% of women suffer an episode of VVC at least once in their lifetime and 5&#8211;8% of women suffer from recurrent VVC (RVVC) (<xref rid="B14" ref-type="bibr">14</xref>). To this date, there still exists no definitive cure for RVVC, which is commonly treated with over-the-counter antifungal medications but continues to relapse&#8201;&#8805;4 times a year for the rest of a woman&#8217;s life (<xref rid="B15" ref-type="bibr">15</xref>).</p><p>Antifungal agents available for the treatment of systemic or mucosal candidiasis are restricted to only a few classes of compounds, such as azoles, polyenes, allylamines, and echinocandins (<xref rid="B16" ref-type="bibr">16</xref>). However, adverse side effects, toxicity, and emergence of drug resistance limit the use of these drugs (<xref rid="B10" ref-type="bibr">10</xref>). In particular, various <italic toggle="yes">Candida</italic> species can acquire resistance to different antifungals or, even worse, to more than one drug (<xref rid="B17" ref-type="bibr">17</xref>&#8211;<xref rid="B20" ref-type="bibr">20</xref>). In fact, the emergence of drug resistance in <italic toggle="yes">Candida</italic> spp. has been on a growing trend over the past decade (<xref rid="B21" ref-type="bibr">21</xref>), with multidrug-resistant <italic toggle="yes">Candida</italic> spp. now being reported all over the world (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>). Finally, the recent discovery of a novel multidrug resistant species of <italic toggle="yes">Candida</italic> (<italic toggle="yes">C. auris</italic>) poses a further threat to our ability to use antifungal drugs to treat candidiasis (<xref rid="B24" ref-type="bibr">24</xref>).</p><p>To reduce the incidence and mortality of opportunistic fungal infections, experts agree that we need (i) improved diagnostics to allow more rapid implementation of appropriate therapies, (ii) more effective antifungal agents associated with less severe side effects, and (iii) to develop immunotherapies based on our mounting knowledge of antifungal immunity (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B25" ref-type="bibr">25</xref>). These same strategies could be used also to reduce the recurrence and severity of RVVC episodes. We hereby argue that an anti-<italic toggle="yes">Candida</italic> vaccine, as long as it was effective in the populations of patients it is intended to protect, could help reduce the global burden of both systemic and vaginal candidiasis bringing about substantial socioeconomic benefits.</p><p>In this review, we first provide an up-to-date overview of various efforts that have been attempted so far in the quest of an anti-<italic toggle="yes">Candida</italic> vaccine, which has remained elusive. We next critically assess potential common problems that might have hindered such efforts and finally propose a few tentative solutions to overcoming those problems.</p></sec><sec id="S2"><title>Current Anti-<italic toggle="yes">Candida</italic> Vaccine Landscape</title><p>In the last decades, several different anti-<italic toggle="yes">Candida</italic> vaccines have been proposed but only few of them have been tested in clinical trials (Table <xref ref-type="table" rid="T1">1</xref>). Here, we will summarize the current anti-<italic toggle="yes">Candida</italic> vaccine landscape and discuss advantages and disadvantages of each vaccination strategy.</p><table-wrap id="T1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Summary of past and current anti-<italic toggle="yes">Candida</italic> vaccine candidates.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Vaccine category</th><th valign="top" align="left" rowspan="1" colspan="1">Description</th><th valign="top" align="left" rowspan="1" colspan="1">Clinical trial stage</th><th valign="top" align="left" rowspan="1" colspan="1">Protection (<italic toggle="yes">C. albicans</italic> infection site)</th><th valign="top" align="left" rowspan="1" colspan="1">Cross-protection (non-<italic toggle="yes">C. albicans</italic> organisms)</th><th valign="top" align="center" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">LA</td><td align="left" valign="top" rowspan="1" colspan="1">Hyphal-defective <italic toggle="yes">C. albicans</italic> strain PCA-2</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">SYS</td><td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">Staphylococcus aureus</italic></td><td align="center" valign="top" rowspan="1" colspan="1">(<xref rid="B26" ref-type="bibr">26</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LA</td><td align="left" valign="top" rowspan="1" colspan="1">MAP kinase-defective <italic toggle="yes">hog1</italic>&#916; <italic toggle="yes">C. albicans</italic> strain CNC13</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">SYS</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">(<xref rid="B27" ref-type="bibr">27</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LA</td><td align="left" valign="top" rowspan="1" colspan="1">Cell wall-defective <italic toggle="yes">ecm33</italic>&#916; <italic toggle="yes">C. albicans</italic> strain RML2U</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">SYS</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">(<xref rid="B28" ref-type="bibr">28</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LA</td><td align="left" valign="top" rowspan="1" colspan="1">Filamentation-repressible <italic toggle="yes">C. albicans</italic> strain tet-NRG1</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">SYS</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">(<xref rid="B29" ref-type="bibr">29</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LA</td><td align="left" valign="top" rowspan="1" colspan="1">Yeast-locked <italic toggle="yes">C. albicans</italic> strain <italic toggle="yes">cph1</italic>&#916;/<italic toggle="yes">efg1</italic>&#916;</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">SYS</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">(<xref rid="B30" ref-type="bibr">30</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LA</td><td align="left" valign="top" rowspan="1" colspan="1">Heat-killed or live <italic toggle="yes">Saccharomyces cerevisiae</italic> clinical strains</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">SYS</td><td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">Aspergillus fumigatus, Cryptococcus grubii, and Coccidioides posadasii</italic></td><td align="center" valign="top" rowspan="1" colspan="1">(<xref rid="B31" ref-type="bibr">31</xref>&#8211;<xref rid="B34" ref-type="bibr">34</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">REC</td><td align="left" valign="top" rowspan="1" colspan="1">Recombinant N-terminus of <italic toggle="yes">C. albicans</italic> Als1p</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">SYS, VAG, OR</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">(<xref rid="B35" ref-type="bibr">35</xref>, <xref rid="B36" ref-type="bibr">36</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">REC</td><td align="left" valign="top" rowspan="1" colspan="1">Recombinant N-terminus of <italic toggle="yes">C. albicans</italic> Als3p</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">SYS, VAG</td><td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">S. aureus</italic></td><td align="center" valign="top" rowspan="1" colspan="1">(<xref rid="B37" ref-type="bibr">37</xref>, <xref rid="B38" ref-type="bibr">38</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">REC</td><td align="left" valign="top" rowspan="1" colspan="1">Recombinant N-terminus of <italic toggle="yes">C. albicans</italic> Als3p plus alum adjuvant (NDV-3)</td><td align="left" valign="top" rowspan="1" colspan="1">Phase II</td><td align="left" valign="top" rowspan="1" colspan="1">SYS, VAG</td><td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">S. aureus</italic></td><td align="center" valign="top" rowspan="1" colspan="1">(<xref rid="B39" ref-type="bibr">39</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">REC</td><td align="left" valign="top" rowspan="1" colspan="1">Recombinant <italic toggle="yes">C. albicans</italic> Sap2p</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">VAG</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">(<xref rid="B40" ref-type="bibr">40</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">REC</td><td align="left" valign="top" rowspan="1" colspan="1">Recombinant <italic toggle="yes">C. albicans</italic> Sap2p (PEV-7)</td><td align="left" valign="top" rowspan="1" colspan="1">Phase I</td><td align="left" valign="top" rowspan="1" colspan="1">VAG</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">(<xref rid="B41" ref-type="bibr">41</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">REC</td><td align="left" valign="top" rowspan="1" colspan="1">Recombinant <italic toggle="yes">C. albicans</italic> Hsp90p (Mycograb)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">SYS</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">(<xref rid="B42" ref-type="bibr">42</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">REC</td><td align="left" valign="top" rowspan="1" colspan="1">Recombinant <italic toggle="yes">C. albicans</italic> Hyr1p</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">SYS</td><td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">C. glabrata, C. krusei, C. parapsilosis and C. tropicalis</italic></td><td align="center" valign="top" rowspan="1" colspan="1">(<xref rid="B43" ref-type="bibr">43</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">EX</td><td align="left" valign="top" rowspan="1" colspan="1">Crude cell wall extract</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">SYS</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">(<xref rid="B44" ref-type="bibr">44</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GC</td><td align="left" valign="top" rowspan="1" colspan="1">Mannans and peptide conjugates</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">SYS</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">(<xref rid="B45" ref-type="bibr">45</xref>, <xref rid="B46" ref-type="bibr">46</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GC</td><td align="left" valign="top" rowspan="1" colspan="1">&#946;-glucan conjugated with MF59 adjuvant</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">VAG</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">(<xref rid="B47" ref-type="bibr">47</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GC</td><td align="left" valign="top" rowspan="1" colspan="1">Laminarin conjugated with diphtheria toxoid (Lam-CRM197)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">SYS, VAG</td><td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">A. fumigatus</italic></td><td align="center" valign="top" rowspan="1" colspan="1">(<xref rid="B48" ref-type="bibr">48</xref>)</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">LA, live attenuated; REC, recombinant; EX, extract; GC, glycoconjugate; SYS, systemic; VAG, vaginal; OR, oral</italic>.</p></table-wrap-foot></table-wrap><p>Historically, vaccines are developed to boost antigen-specific immune responses and elicit protective immunological memory against specific pathogenic strains. In the case of <italic toggle="yes">Candida</italic> species, most of the efforts have been focused around the most common species, <italic toggle="yes">C. albicans</italic>. Different strategies have been used to immunize hosts against candidiasis: (i) live-attenuated strains, (ii) recombinant proteins, and (iii) glycoconjugates.</p><sec id="S2-1"><title>Live-Attenuated Vaccines</title><p>The first ever reported vaccine, Edward Jenner&#8217;s famous vaccinia virus, was a live virus causing cowpox in cattle but protecting humans against smallpox (<xref rid="B49" ref-type="bibr">49</xref>). By all definitions, it was a live-attenuated vaccine, which caused only a very mild form of the disease in humans while at the same time raising long-lasting protective immune memory. Up to this date, most currently available antiviral vaccines (e.g., yellow fever, measles, varicella) and some antibacterial ones (e.g., BCG) are essentially live-attenuated versions of their pathogenic counterparts. Because of this long history of success, it is not surprising that several studies have ascribed various attenuated strains of <italic toggle="yes">C. albicans</italic> the ability to confer protection against candidiasis.</p><p>The morphogenetic transition between the conidial (yeast) and hyphal (filamentous) form is one of the most important virulence factors in <italic toggle="yes">C. albicans</italic> (<xref rid="B50" ref-type="bibr">50</xref>); for this reason, the absence of filamentation is a common characteristic of attenuated strains of this species. Several <italic toggle="yes">C. albicans</italic> mutants associated with no or low virulence, including PCA-2 (incapable of yeast-hyphae conversion), CNC13 (deleted in the MAP kinase <italic toggle="yes">HOG1</italic>), RML2U [deleted in the cell wall protein (CWP) gene <italic toggle="yes">ECM33</italic>], and tet-NRG1 (in which the filamentation repressor <italic toggle="yes">NRG1</italic> can be overexpressed by doxycycline), have been used to immunize mice and shown to protect them from a subsequent lethal systemic infection with a virulent strain (<xref rid="B26" ref-type="bibr">26</xref>&#8211;<xref rid="B29" ref-type="bibr">29</xref>). Also, the <italic toggle="yes">C. albicans</italic> double-mutant <italic toggle="yes">cph1</italic>/<italic toggle="yes">efg1</italic>, which is severely impaired in hyphal morphogenesis, partially protects mice from systemic infection by a wild-type <italic toggle="yes">C. albicans</italic> strain (<xref rid="B30" ref-type="bibr">30</xref>).</p><p>Not only <italic toggle="yes">C. albicans</italic> attenuated strains have been used to protect against systemic candidiasis, but also the generally regarded-as-safe baker&#8217;s yeast <italic toggle="yes">Saccharomyces cerevisiae</italic> has been successfully used to this end. Stevens and colleagues have described the use of heat-killed or live <italic toggle="yes">S. cerevisiae</italic> as a protective vaccine against <italic toggle="yes">C. albicans</italic> infection, but also against <italic toggle="yes">A. fumigatus, Cryptococcus grubii</italic>, and <italic toggle="yes">Coccidioides</italic> infection in a dose-dependent manner (<xref rid="B31" ref-type="bibr">31</xref>&#8211;<xref rid="B34" ref-type="bibr">34</xref>).</p><p>Despite these success stories at the basic research level, none of these vaccine candidates has progressed to clinical trials. Possible reasons include the fact that characterization of these strains is complex, that the stability of the virulence-attenuating mutations is not guaranteed, and that the use of live-attenuated vaccines is currently not recommended in immunocompromised patients due to their weaker immune defense and the higher probability to develop a disease.</p></sec><sec id="S2-2"><title>Recombinant Proteins</title><p>In contrast to live <italic toggle="yes">Candida</italic> vaccines (how attenuated they may be), recombinant vaccines are generally perceived as potentially safer to the human host, because they do not contain any infectious agent. This characteristic makes recombinant protein vaccines more suitable especially for the immunocompromised individuals that would most benefit from such a vaccine. In general, this strategy has focused on proteins expressed on the surface of the fungus, such as CWPs or adhesion proteins, to ensure that epitopes would be easily accessible and &#8220;visible&#8221; by the immune system. Efforts also often concentrated on proteins critical to virulence, such as hyphal-specific effectors, in order to mount immune responses specifically against the pathogenic forms of the fungus. Besides, current work has shown that the strongest adaptive immune memory responses are often directed toward hyphal-associated proteins.</p><sec id="S2-2-1"><title>Agglutinin-Like Sequence Proteins</title><p>Agglutinin-like sequence (Als) proteins are located at the surface of <italic toggle="yes">C. albicans</italic> and play important roles in the adhesion to human endothelial cells and in the development of invasive candidiasis (<xref rid="B51" ref-type="bibr">51</xref>). Because these proteins are both exposed on the fungal surface and important for invasion of host cells, several vaccines have been proposed against invasive candidiasis using recombinant versions of various Als proteins, including Als1p and Als3p, formulated with or without adjuvants.</p><p>The recombinant N-terminus of Als1 (rAls1p-N) was produced and purified from <italic toggle="yes">S. cerevisiae</italic> and used in combination with Complete Freund&#8217;s Adjuvant (CFA) subcutaneously and boosted with different doses of rAls1p-N with Incomplete Freund&#8217;s Adjuvant (IFA) at day 21 post-immunization; lethal challenge with live <italic toggle="yes">C. albicans</italic> showed a survival rate of 50&#8211;57% and a decrease in fungal burden (<xref rid="B36" ref-type="bibr">36</xref>). This vaccine was deemed effective and improved survival in both immunocompetent and neutropenic mice and in murine models of oropharyngeal candidiasis and <italic toggle="yes">Candida</italic> vaginitis (<xref rid="B35" ref-type="bibr">35</xref>).</p><p>Vaccination with the recombinant N-terminus of Als3 (rAls3p-N) induced a stronger antibody response and survival rate compared with the rAls1p-N vaccine, and was more effective than rAls1p-N in the murine model of oropharyngeal and vaginal candidiasis (<xref rid="B37" ref-type="bibr">37</xref>). Interestingly, it showed also protection against <italic toggle="yes">S. aureus</italic> infection (<xref rid="B38" ref-type="bibr">38</xref>), suggesting the existence of shared immune epitopes between these distantly related species; consistently, <italic toggle="yes">Candida</italic> Als3p is structurally similar to a clumping factor of <italic toggle="yes">S. aureus</italic> (<xref rid="B52" ref-type="bibr">52</xref>).</p><p>Bar et al. identified an antigenic peptide by immunoproteomic approaches called pAls, widely conserved in many non-<italic toggle="yes">Candida</italic> species; this epitope mediates T-cell-dependent protection from invasive candidiasis. This pAls epitope is found in the Als3 protein and the authors suggest an implication of this epitope in the protective effect of the Als3 vaccine (<xref rid="B53" ref-type="bibr">53</xref>).</p><p>NDV-3A, a rAls3p-N vaccine formulated with Alhydrogel adjuvant, has been tested in a phase-I clinical trial. The trial was performed on 40 healthy volunteers and showed an increase in antibody titers at two different doses, as well as increased cytokine responses and IgG and IgA<sub>1</sub> titers in the revaccinated subjects (<xref rid="B39" ref-type="bibr">39</xref>). A few adverse events have been described, but overall the vaccine was well tolerated by the subjects and hence the results were deemed as promising. Like the version of rAls3p-N vaccine without adjuvant, NDV-3 also showed activity against <italic toggle="yes">S. aureus</italic> infection, further corroborating the idea that the vaccination with <italic toggle="yes">Candida</italic> antigens containing epitope homologs found in other organisms can be harnessed to generate &#8220;convergent immunity.&#8221; NDV-3A is now in a phase-II clinical trial to test the immunotherapeutic effect of the vaccine in women with RVVC.<xref ref-type="fn" rid="fn1"><sup>1</sup></xref></p></sec><sec id="S2-2-2"><title>Secreted Aspartil Proteases</title><p>Secreted Aspartil Proteases (SAP) constitute a family of 10 proteins secreted by <italic toggle="yes">C. albicans</italic>, which are required for adhesion, epithelial, and endothelial invasion and fungal cell metabolism (<xref rid="B54" ref-type="bibr">54</xref>, <xref rid="B55" ref-type="bibr">55</xref>). Sap2p is the most abundantly expressed SAP in <italic toggle="yes">C. albicans</italic> and its recombinant form has been used to immunize rats intravaginally or intranasally, either using cholera toxin as an adjuvant or without an adjuvant; the vaccination resulted in the clearance of the <italic toggle="yes">Candida</italic> vaginal infection (<xref rid="B40" ref-type="bibr">40</xref>). The same research group also developed PEV7, a truncated version of Sap2p (amino acids 77&#8211;400) incorporated into the lipid bilayer of influenza virosomes. Because preclinical data demonstrated that intramuscularly vaccinated rats showed protection against vaginal candidiasis (<xref rid="B41" ref-type="bibr">41</xref>), PEV7 has progressed to clinical trials as a therapeutic vaccine for the treatment of RVVC. In a randomized phase-I trial, the subjects, whether immunized <italic toggle="yes">via</italic> intramuscular injections or by intravaginal capsules, showed a strong B-cell-mediated immune response in vaginal and cervical samples. All volunteers showed a mucosal immune response with consistently high titers across the groups, the response was dose-dependent and no serious adverse events were reported.<xref ref-type="fn" rid="fn2"><sup>2</sup></xref></p></sec><sec id="S2-2-3"><title>Heat Shock Protein 90 (Hsp90p)</title><p>Heat shock protein 90 is a highly conserved stress-induced chaperone, with key functions in setting cellular responses to stressful stimuli, which is indispensable for yeast viability and located in the cell wall of <italic toggle="yes">C. albicans</italic>. The 47-kDa carboxyl fragment of <italic toggle="yes">C. albicans</italic> Hsp90 had been identified as a <italic toggle="yes">Candida</italic> antigen in different studies (<xref rid="B56" ref-type="bibr">56</xref>). This antigen is very abundant and immunogenic, and the presence of antibodies against Hsp90 correlates with good prognosis, whereas low levels are associated with mortality (<xref rid="B57" ref-type="bibr">57</xref>). Various Hsp90 epitopes (LSREM, LKVIRK, and DEPAGE) have been identified using a phage-display library and shown to induce Hsp90-specific serum antibodies and to prolong survival in a mouse model of systemic candidiasis (<xref rid="B42" ref-type="bibr">42</xref>). A recombinant protein called Mycograb, consisting of cross-linked Hsp90 NKILKVIRKNIVKK peptide-binding variable domains of human antibody heavy and light chains, was constructed and expressed in <italic toggle="yes">Escherichia coli</italic>. When combined with amphotericin B, Mycograb produced significant improvement in patients with invasive candidiasis (<xref rid="B58" ref-type="bibr">58</xref>, <xref rid="B59" ref-type="bibr">59</xref>). However, the drug was refused by the European Medicines Agency on the grounds of product safety and quality, and its ability to potentiate the effects of amphotericin B were later found to be non Hsp90-specific (<xref rid="B60" ref-type="bibr">60</xref>).</p></sec><sec id="S2-2-4"><title>Hyphally Regulated Proteins</title><p>Hyphally regulated 1 (Hyr1) is a glycosyl phosphatidylinositol (GPI)-anchor mannoprotein that is expressed during hyphal formation on the cell wall of <italic toggle="yes">C. albicans</italic>. A recombinant version of the N-terminus of Hyr1 (rHyr1p-N) was produced in <italic toggle="yes">E. coli</italic> and used to immunize mice <italic toggle="yes">via</italic> subcutaneous injection with either CFA or aluminum hydroxide and boosted on day 21 with IFA. After 2&#8201;weeks, vaccinated mice were challenged with a lethal dose of <italic toggle="yes">C. albicans</italic> and non-albicans <italic toggle="yes">Candida</italic> (NAC) species. The vaccine was effective against infections by <italic toggle="yes">C. albicans, C. glabrata, C. krusei, C. parapsilosis</italic>, and <italic toggle="yes">C. tropicalis</italic> in both immunocompetent and neutropenic mice (<xref rid="B43" ref-type="bibr">43</xref>).</p></sec><sec id="S2-2-5"><title>CWP Extracts</title><p>Not only purified recombinant proteins, but also crude <italic toggle="yes">C. albicans</italic> cell wall extracts, seem to be effective to protect against invasive candidiasis. In fact, subcutaneous immunization with &#946;-mercaptoethanol-extracted <italic toggle="yes">C. albicans</italic> CWPs in combination with Ribi Adjuvant System (RAS) R-700 followed by a booster injected 21&#8201;days after the first immunization, conferred protection in 75% of immunized mice after a lethal challenge with <italic toggle="yes">C. albicans</italic> (<xref rid="B44" ref-type="bibr">44</xref>). However, such crude preparations are unlikely to progress to clinical trials due to the difficulty in characterizing and standardizing such complex vaccine formulations.</p></sec></sec><sec id="S2-3"><title>Glycoconjugates</title><p>An alternative to protein-based vaccines is to use glycans commonly found in fungal cell walls but absent in host cells. In fact, the <italic toggle="yes">Candida</italic> cell wall represents a hub of pathogen-associated molecular pattern (PAMP)&#8211;pathogen recognition receptor (PRR) interactions that dictate downstream immune responses (<xref rid="B61" ref-type="bibr">61</xref>). For these reasons, various cell wall polysaccharides have been tested as vaccine targets against systemic candidiasis.</p><sec id="S2-3-1"><title>Mannans and Derivative Peptide Conjugates</title><p>Mannans are polymers of <italic toggle="yes">O</italic>-linked or <italic toggle="yes">N</italic>-linked mannosides attached to CWPs and constitute the outermost, and hence most accessible, layer of the <italic toggle="yes">C. albicans</italic> cell wall. While <italic toggle="yes">O</italic>-mannans are predominately recognized by TLR4 (<xref rid="B62" ref-type="bibr">62</xref>), <italic toggle="yes">N</italic>-mannans are recognized by a multitude of receptors, including the Mannose Receptor (MR), DC-SIGN, Dectin-2, Galectin-3, and Mincle (<xref rid="B63" ref-type="bibr">63</xref>). Classically, <italic toggle="yes">Candida</italic> mannans have been attributed immunesuppressive properties (<xref rid="B64" ref-type="bibr">64</xref>); but the discovery that <italic toggle="yes">N</italic>-linked mannans are critically required for recognition by DC-SIGN and MR on human dendritic cells (DCs) has established a rational for conjugating them to antigenic peptides. Consistent with this idea, mannosylated antigens were shown to be presented more effectively than non-mannosylated forms (<xref rid="B65" ref-type="bibr">65</xref>).</p><p>In one example, researchers have used computational epitope searches to select 6 peptides in <italic toggle="yes">C. albicans</italic> CWPs (fructose-bisphosphate aldolase; methyltetrahydropteroyltriglutamate; hyphal wall protein-1; enolase; glyceraldehyde-3-phosphate dehydrogenase; and phosphoglycerate kinase) and conjugated these peptides with &#946;-mannans to generate the first series of fully synthetic glycopeptide vaccines against systemic candidiasis. Depending on the specific peptide, the immunized mice showed 80&#8211;100% survival and reduced kidney fungal burden after the challenge with <italic toggle="yes">C. albicans</italic> (<xref rid="B45" ref-type="bibr">45</xref>).</p><p>More recent studies showed than the vaccination with BSA-based conjugates bearing synthetic &#945;-1,6-branched oligomannosides induced humoral responses in mice and induced production of potentially protective antibodies (<xref rid="B46" ref-type="bibr">46</xref>). Immunization with <italic toggle="yes">Candida</italic> mannan-derived branched 3,6-di-<italic toggle="yes">O</italic>-substituted &#945;-oligomannosides conjugated to BSA (M5-BSA and M6-BSA conjugates) induced similar levels of CD19<sup>+</sup> B lymphocytes, but the candidacidal activity of polymorphonuclear leukocytes induced by opsonization with M6-BSA antisera was higher than that with M5-BSA, thus revealing some important differences in their ability to induce an effective and protective immune response against <italic toggle="yes">Candida</italic> infection (<xref rid="B66" ref-type="bibr">66</xref>). A better mechanistic understanding of the type of immune responses elicited by various <italic toggle="yes">Candida</italic> mannans is therefore required before these compounds can progress to clinical studies.</p></sec><sec id="S2-3-2"><title>&#946;-Glucan and Derivative Conjugate Vaccines</title><p>Directly underneath mannans lies a hidden layer of &#946;-glucans, which is an essential component of the <italic toggle="yes">Candida</italic> cell wall (<xref rid="B67" ref-type="bibr">67</xref>) and elicits Dectin-1-dependent innate immune responses that are critical for host protection against fungi (<xref rid="B68" ref-type="bibr">68</xref>). Moreover, &#946;-glucans from the <italic toggle="yes">C. albicans</italic> cell wall are highly immunogenic, leading to epigenetic and metabolic reprogramming of monocytes/macrophages, elevated cytokine responses and to innate host protection against systemic candidiasis (<xref rid="B69" ref-type="bibr">69</xref>&#8211;<xref rid="B71" ref-type="bibr">71</xref>). This phenomenon was termed &#8220;trained immunity&#8221; (<xref rid="B72" ref-type="bibr">72</xref>) and is discussed further in Section &#8220;<xref ref-type="sec" rid="S4-2">Trained Immunity&#8212;Toward the Next Generation of Vaccines?</xref>&#8221;</p><p>When used in combination with the MF59 adjuvant (oil-in-water emulsion of squalene oil), fungal-derived &#946;-glucan showed protection against murine vaginal candidiasis but is currently not approved for use in humans (<xref rid="B47" ref-type="bibr">47</xref>). The conjugation of the &#946;-glucan preparation Laminarin (a soluble Dectin-1 ligand derived from seaweed) with diphtheria toxoid (Lam-CRM197) resulted, in murine models, in significant protection against systemic candidiasis, as well as cross-protection against aspergillosis (<xref rid="B48" ref-type="bibr">48</xref>). In further studies, researchers conjugated the diphtheria toxoid with various other &#946;-glucan preparations, such as curdlan (a high-molecular-weight &#946;-1,3-linked polymer produced by bacteria) or synthetic oligosaccharides that contained either only linear &#946;-1,3 linkages or also branched &#946;-1,6 linkages, and combined it with the MF59 adjuvant. Interestingly, conjugates raising antibodies against &#946;-1,3-glucans were protective in a mouse model of systemic candidiasis, while anti-&#946;-1,6-antibodies appeared to reverse this effect (<xref rid="B73" ref-type="bibr">73</xref>). Overall these studies reveal the high immunogenicity of &#946;-glucans but also a surprisingly complex relationship between antifungal immune responses and host protection against fungal infections. Moreover, different <italic toggle="yes">Candida</italic> species expose &#946;-glucan on their surface to different degrees (<xref rid="B74" ref-type="bibr">74</xref>), questioning how broadly protective such vaccines would be against various candidiasis-causing agents. These complexities will need to be better understood, before these polysaccharides can be translated into safe and effective antifungal vaccines for human use.</p></sec></sec></sec><sec id="S3"><title>Common Challenges Faced so Far</title><p>The fact that <italic toggle="yes">C. albicans</italic> is thought to have coevolved with humans for at least the past 2,000&#8201;years (<xref rid="B75" ref-type="bibr">75</xref>), that it is a lifelong inhabitant of humans that colonizes the gastrointestinal (GI) tract since birth (<xref rid="B76" ref-type="bibr">76</xref>) and that is then transmitted between family members (<xref rid="B77" ref-type="bibr">77</xref>), poses a few conceptual and technical challenges in the development of an anti-<italic toggle="yes">Candida</italic> vaccine. On one hand, this long interaction history with the human GI tract suggests that these fungi might have evolved a series of mechanisms to escape various host immune defenses, including a high genetic, phenotypic and morphological plasticity (<xref rid="B78" ref-type="bibr">78</xref>). On the other hand, humans might have learned to recognize <italic toggle="yes">Candida</italic> species as commensals and might have therefore developed immune tolerance toward them&#8212;breaking this tolerance is expected to be both difficult and in some cases even counterproductive (<xref rid="B79" ref-type="bibr">79</xref>). Lastly, the highest risk group for <italic toggle="yes">Candida</italic>-related infections is represented by immunocompromised and immunosuppressed patients, i.e., a class of individuals that is intrinsically less responsive to immunization. Here, we will outline each of these issues in greater detail, and later we will attempt to offer some possible ways forward based on recent learning points.</p><sec id="S3-1"><title>Zeroing in on a Moving Target</title><sec id="S3-1-1"><title>Morphological and Phenotypic Plasticity of <italic toggle="yes">C. albicans</italic></title><p>A first difficulty encountered when designing an anti-<italic toggle="yes">Candida</italic> vaccine lies in the morphological and phenotypic plasticity of these fungi (Figure <xref ref-type="fig" rid="F1">1</xref>), which makes them almost &#8220;moving targets.&#8221; In fact, <italic toggle="yes">C. albicans</italic> is a polymorphic fungus that can reversibly transition between yeast, pseudohyphal and hyphal forms&#8212;a property that is closely linked to its evolutionary adaptation to life inside the human host. When <italic toggle="yes">C. albicans</italic> grows in its unicellular yeast form, it is commonly regarded as a harmless colonizer, while its switching to the hyphal form is related to pathogenesis, in that hyphae adhere to and invade epithelial cells resulting in extensive damage to host cells (<xref rid="B80" ref-type="bibr">80</xref>).</p><fig id="F1" position="float" orientation="portrait"><label>Figure 1</label><caption><p>Sources of variability in <italic toggle="yes">Candida</italic>-related infections. The figure illustrates the plethora of variations at the level of the pathogen and the host, which pose serious challenges in the development of an antifungal vaccine. On the pathogen side, <italic toggle="yes">Candida</italic> species display large phenotypic, morphological, and genetic variation and dynamics; on the host side, candidiasis can occur in different types of patients, with different types of immune system dysfunction or carrying different genetic polymorphisms, and in different anatomical sites. Taken together, this broad and diverse clinical spectrum of the disease makes it difficult to design a &#8220;one-size-fits-all&#8221; vaccine that would protect all these different patients from all these different types of fungal infection.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fimmu-09-00897-g001.jpg"/></fig><p>Interestingly, <italic toggle="yes">C. albicans</italic> isolated from the blood of patients with candidiasis often matches those recovered from the GI tract of the same patients (<xref rid="B81" ref-type="bibr">81</xref>), suggesting that <italic toggle="yes">C. albicans</italic> invades the bloodstream directly from the GI tract. How exactly the GI barrier is crossed is currently not completely understood, but it is thought to be mediated by or facilitated by epithelial tissue damage; and that <italic toggle="yes">C. albicans</italic> hyphal formation might be critical for this ability (<xref rid="B82" ref-type="bibr">82</xref>). Therefore, hyphal-specific or hyphal-associated CWPs such as Hyr1, Hwp2, Plb5, and Sod5 have all been proposed as vaccine target candidates (<xref rid="B83" ref-type="bibr">83</xref>).</p><p>However, vaccines against hyphal CWPs alone may not be sufficient to provide immune protection. While direct penetration into the mucosal surfaces by the hyphal form is important for invasion, widespread dissemination through the bloodstream and to the organs is thought to be facilitated by the yeast form (<xref rid="B84" ref-type="bibr">84</xref>). As both yeast and hyphae are detected in patients with candidiasis (<xref rid="B85" ref-type="bibr">85</xref>), and some mutants defective in filamentation displayed similar virulence as the wild type (<xref rid="B86" ref-type="bibr">86</xref>), it is the plasticity of this morphological switch, rather than the hyphal form alone, that appears to critically underlie the virulence of <italic toggle="yes">C. albicans</italic>. The variety of different forms of <italic toggle="yes">C. albicans</italic> that exist in various organs may represent a further challenge in vaccine development. For example, in mouse infection models, while <italic toggle="yes">C. albicans</italic> is mainly observed in the hyphal form in the kidney, it actually persists as a yeast in the spleen and the liver (<xref rid="B87" ref-type="bibr">87</xref>). To achieve sterile protection, the ideal vaccine should be able to stimulate clearance of the fungus not only in the former but also in the latter organs.</p><p>A second form of plasticity in <italic toggle="yes">C. albicans</italic> is a heritable white-to-opaque phenotypic switch. Smooth and white colonies are observed during the white phase, while elongated and rod-like cells giving rise to flattened gray colonies appear in the opaque phase (<xref rid="B88" ref-type="bibr">88</xref>). Opaque cells are less virulent than white cells in mouse bloodstream infection model (<xref rid="B89" ref-type="bibr">89</xref>, <xref rid="B90" ref-type="bibr">90</xref>) and undergo filamentation in response to stimuli that are distinct form white cells (<xref rid="B91" ref-type="bibr">91</xref>). The switching between white and opaque phenotypes may facilitate <italic toggle="yes">C. albicans</italic> to evade from host immune response, as opaque cells are less susceptible to be phagocytosed by macrophages (<xref rid="B92" ref-type="bibr">92</xref>) and also capable to evade killing by neutrophils (<xref rid="B93" ref-type="bibr">93</xref>).</p><p>Another phenotypic switch, known as gastrointestinally induced transition (GUT) and found as a result of <italic toggle="yes">WOR1</italic> overexpression, was recently described to confer increased fitness of <italic toggle="yes">C. albicans</italic> in the GI tract of antibiotic-treated mice (<xref rid="B94" ref-type="bibr">94</xref>). While GUT cells share some resemblance with opaque cells, such as a reduced virulent in mouse bloodstream infections, they appear to be transcriptionally distinct from both white and opaque cells, therefore likely representing an independent epigenetic state. Whether GUT cells also arise in mucosal or systemic infections in humans and whether these cells express specific factors that are important for disease remains to be determined, but their discovery nonetheless sheds light on additional layers of complexity in the morphological and phenotypic plasticity of this fungal pathogen.</p><p>As a whole, morphological and phenotypic plasticity renders <italic toggle="yes">C. albicans</italic> a &#8220;skilled transformer&#8221; (<xref rid="B78" ref-type="bibr">78</xref>). Therefore, vaccines directed against single targets expressed only in a particular fungal form may not be sufficient to raise protective immune responses against the entire arsenal of antigens and virulence factors that are dynamically presented to the host in different organs at different times.</p></sec><sec id="S3-1-2"><title>Genomic Plasticity of <italic toggle="yes">Candida albicans</italic></title><p><italic toggle="yes">Candida albicans</italic>, apart from morphological and phenotypic transitions, also displays a high degree of genomic plasticity including gross chromosome rearrangement, aneuploidy and loss of heterozygosity when exposed to different stresses. Such genomic changes equip <italic toggle="yes">C. albicans</italic> to rapidly adapt to an adverse environment by changing the copy number of specific genes on a given chromosome (<xref rid="B95" ref-type="bibr">95</xref>). One of the well-known examples is the identification of an isochromosome composed of two copies of the left arm of chromosome 5, which is associated with azole resistance (<xref rid="B17" ref-type="bibr">17</xref>) due to amplification of two resistance genes, <italic toggle="yes">ERG11</italic> and <italic toggle="yes">TAC1</italic> (<xref rid="B96" ref-type="bibr">96</xref>). Genomic variations are commonly observed in clinical <italic toggle="yes">C. albicans</italic> isolates, which includes copy number variations, chromosomal inversions, subtelomeric hypervariation, loss of heterozygosity and aneuploidy (<xref rid="B97" ref-type="bibr">97</xref>). Moreover, <italic toggle="yes">C. albicans</italic> with increased DNA content (aneuploidy) occurs at a higher frequency in clinical blood isolates when compared with mucosal isolates (<xref rid="B98" ref-type="bibr">98</xref>). This suggests that acquisition of aneuploidy, and the consequent copy number alteration of specific genes, may provide a rapid mechanism to modify the expression pattern of certain antigens that were originally targeted by a certain vaccine.</p></sec><sec id="S3-1-3"><title>Non-albicans <italic toggle="yes">Candida</italic> Species</title><p>The genus <italic toggle="yes">Candida</italic> represents a highly heterogeneous group of&#8201;&gt;50 known species. Nevertheless, &gt;90% of the invasive <italic toggle="yes">Candida</italic> infections are caused by <italic toggle="yes">C. albicans, C. glabrata, C. parapsilosis, C. tropicalis</italic> or <italic toggle="yes">C. krusei</italic> (<xref rid="B99" ref-type="bibr">99</xref>). While this figure has remained largely unchanged, the relative ranking between these species has seen significant shifts in different regions over the past decades (<xref rid="B100" ref-type="bibr">100</xref>). While <italic toggle="yes">C. albicans</italic> is still considered the most common species causing candidemia, increasing rates of NAC species in candidemia have been reported worldwide (<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B101" ref-type="bibr">101</xref>, <xref rid="B102" ref-type="bibr">102</xref>). Moreover, significant variations of <italic toggle="yes">Candida</italic> species are detected in different patient groups and geographical regions (<xref rid="B103" ref-type="bibr">103</xref>). For instance, <italic toggle="yes">C. glabrata</italic> has emerged as an important pathogen in northern Europe, the United States and Canada with a higher rate of incidence in adults than in children, and lower in neonates (<xref rid="B104" ref-type="bibr">104</xref>). <italic toggle="yes">C. parapsilosis</italic>, instead, is more prominent in southern Europe, Asia, and South America and is mostly associated with low-birth-weight neonates and transplant recipients (<xref rid="B105" ref-type="bibr">105</xref>). Finally, <italic toggle="yes">C. tropicalis</italic> constitutes 20&#8211;45% of <italic toggle="yes">Candida</italic> isolates in the Asia-Pacific region (<xref rid="B18" ref-type="bibr">18</xref>) and invasive candidiasis due to this species is commonly associated with patients with neutropenia and malignancy (<xref rid="B106" ref-type="bibr">106</xref>). Recently, the emergence of <italic toggle="yes">C. auris</italic>, first reported in 2009 in Japan, highlights a new challenge of antifungal treatment, as <italic toggle="yes">C. auris</italic> is often multi-drug resistant and also difficult to be diagnosed with standard laboratory methods, which is contributing to its rapid spreading over multiple countries (<xref rid="B107" ref-type="bibr">107</xref>). In addition to NAC, multispecies candidemia is also emerging as a threat (<xref rid="B108" ref-type="bibr">108</xref>). Taken together, these observations suggest that vaccines specifically against <italic toggle="yes">C. albicans</italic> alone may not be sufficient to provide protection against candidiasis caused by other emerging NAC species or mixed <italic toggle="yes">Candida</italic> species infections.</p></sec></sec><sec id="S3-2"><title>Breaking Immune Tolerance Toward Fungi</title><p>A microbial ecosystem in the human intestine, known as the gut microbiome, harbors more than 100 trillion microorganisms and thus immunological tolerogenic responses are required in order to maintain gut homeostasis and prevent chronic inflammation (<xref rid="B109" ref-type="bibr">109</xref>). Immune tolerance toward human gut commensals, such as <italic toggle="yes">Bacteroides fragilis</italic> and certain <italic toggle="yes">Clostridia</italic> species, is maintained by regulatory T (Treg) cell responses (<xref rid="B110" ref-type="bibr">110</xref>&#8211;<xref rid="B112" ref-type="bibr">112</xref>). Apart from bacteria, <italic toggle="yes">Candida</italic> species are the most common fungal species found in the GI tract; it is therefore reasonable to assume that similar tolerance mechanisms might have evolved to regulate the commensal relationship between humans and fungi. One such mechanism, which likely resulted from the coevolution of bacterial microbiota, commensal fungi and host immune system, relies on the metabolic tryptophan-AhR pathway and 2,3-indoleamine dioxygenase (IDO) (<xref rid="B113" ref-type="bibr">113</xref>, <xref rid="B114" ref-type="bibr">114</xref>). <italic toggle="yes">C. albicans</italic>, being a lifelong inhabitant of humans that colonizes the GI tract since birth (<xref rid="B76" ref-type="bibr">76</xref>), is able to induce IDO expression in DCs. IDO-expressing DCs then promote tolerogenic Treg responses, probably facilitating the switch from pathogenicity to commensalism in <italic toggle="yes">C. albicans</italic> (<xref rid="B115" ref-type="bibr">115</xref>).</p><p>The existence of immunological tolerance toward <italic toggle="yes">C. albicans</italic> and probably other <italic toggle="yes">Candida</italic> species poses two serious challenges for anti-<italic toggle="yes">Candida</italic> vaccine development. First, unlike obligate pathogens with no commensal relationship with humans, this tolerance represents an additional hurdle toward establishment of effective and protective immunological memory. Second, much of the clinical manifestations of <italic toggle="yes">Candida</italic>-related infections are more due to host-derived immunopathology than to pathogen-derived host damage (<xref rid="B116" ref-type="bibr">116</xref>, <xref rid="B117" ref-type="bibr">117</xref>). For instance, mice lacking the chemokine receptor Ccr1, which is critical for neutrophil recruitment, display improved renal function during invasive candidiasis (<xref rid="B118" ref-type="bibr">118</xref>) and administration of Ccr1 antagonists reduces renal tissue injury and improves survival in mice challenged with systemic candidiasis (<xref rid="B119" ref-type="bibr">119</xref>).</p><p>It has thus been argued that a careful balance between immunity and tolerance must be established to maintain commensalism (<xref rid="B79" ref-type="bibr">79</xref>). Breaking host tolerance against fungi and the self-regulated equilibrium between Th17 and Treg responses might lead to undesired consequences, such as exacerbating fungal disease progression or other underlying inflammatory or autoimmune conditions.</p></sec><sec id="S3-3"><title>Vaccinating Patients With No Immunity</title><p>Fungal infections, especially invasive ones, most frequently occur in individuals with compromised or suppressed immunity. Hence, it appears that the patients that would mostly benefit from a future antifungal vaccine are also those least likely to respond to it. Is such an effort then even justified? Or is it doomed to fail from the start? Answers to these questions are more complex than one might expect.</p><p>Efficacy and safety are always a primary concern in any vaccine development effort, and especially so in vulnerable subjects such as patients with lowered immune defenses. As mentioned, the risk of <italic toggle="yes">Candida</italic> infection is especially high in patients with neutropenia, hematological malignancies, solid-organ transplants, prolonged treatment with corticosteroids, long-term ICU stay, chemotherapy and HIV infection (<xref rid="B120" ref-type="bibr">120</xref>). The ideal anti-<italic toggle="yes">Candida</italic> vaccine should possess all of the following properties: (i) zero risk of causing a <italic toggle="yes">Candida</italic>-related infection or to exacerbate the immunopathology associated with an ongoing or future fungal infection, (ii) be immunogenic enough to elicit protection in patients with little or no immunity, (iii) do not increase the risk of aggravating any underlying disease. While this may sound like a &#8220;catch-22,&#8221; vaccinating immunocompromised patients has been attempted with various degrees of success in the past for other kinds of infection.</p><p>For instance, a single-dose of the pneumococcal vaccine was recently deemed safe and immunogenic in children under active immunosuppressive therapy (<xref rid="B121" ref-type="bibr">121</xref>). However, low immunogenicity of the meningococcal vaccine was reported in solid-organ transplant recipients (<xref rid="B122" ref-type="bibr">122</xref>). Lower immunogenicity against the influenza vaccine is generally reported in immunocompromised patients when compared with healthy individuals (<xref rid="B123" ref-type="bibr">123</xref>). However, using a high-dose influenza vaccine was reported to be more immunogenic than the standard dose in children and young adults with leukemia or solid tumors, although not in those with HIV (<xref rid="B124" ref-type="bibr">124</xref>).</p><p>What is progressively becoming clearer is that a &#8220;one-size-fits-all&#8221; anti-<italic toggle="yes">Candida</italic> vaccine may never see the light. For example, a vaccine effective in preventing candidemia in neutropenic cancer patients might not be effective in T-cell-deficient HIV or transplant patients and <italic toggle="yes">vice versa</italic>. As a whole, one of the greatest challenges of any antifungal vaccine will be to deal with the large diversity of underlying disease states and of the associated types of immunosuppression that characterizes this highly heterogeneous risk group (Figure <xref ref-type="fig" rid="F1">1</xref>).</p></sec></sec><sec id="S4"><title>Back to the Future: New Vaccine Strategies on the Horizon?</title><sec id="S4-1"><title>Multivalent Vaccines</title><p>Some monovalent vaccines, i.e., those directed against a single strain or a single antigen, are very effective. A good example is represented by the measles vaccine, which has almost completely eradicated the disease in countries where it has been employed consistently throughout the population (<xref rid="B125" ref-type="bibr">125</xref>). However, the most recent vaccines tend to be multivalent, i.e., they carry multiple antigens of two or more strains/serotypes of the same pathogen. An example is the quadrivalent meningococcal vaccine that protects against 4 serogroups (A, C, W-135, and Y) of meningococci. The quadrivalent vaccine was shown to be more effective in reducing invasive meningococcal disease incidence when compared with the monovalent C vaccine (<xref rid="B126" ref-type="bibr">126</xref>). Another example is the 13-valent pneumococcal conjugate vaccine (PCV13) containing antigens from 13 serotypes of pneumococci. A replacement of the seven-valent pneumococcal conjugate vaccine (PCV7) with PCV13 covering additional six of the most prevalent serotypes that are not included in PCV7 successfully reduced the burden of pneumococcal disease in pediatric populations (<xref rid="B127" ref-type="bibr">127</xref>).</p><p>As <italic toggle="yes">C. albicans</italic> itself expresses a range of virulence factors and several NAC species also carry their own species-specific virulence factors, the recent development of univalent subunit vaccines may face practical obstacles. Considering above success stories of multivalent vaccines applied to bacterial infections, it has been argued that a better approach toward the development of an anti-<italic toggle="yes">Candida</italic> vaccine would be to simultaneously target multiple unrelated virulence-associated antigens (<xref rid="B78" ref-type="bibr">78</xref>). The predicted advantages include the lower probability of selecting &#8220;escape mutants&#8221; and a higher selectively against the pathogenic form of <italic toggle="yes">C. albicans</italic>, thus sparing the commensal&#8212;and perhaps beneficial&#8212;form of this gut inhabitant. In particular, it was proposed to combine a few of the univalent vaccines that have so far progressed furthest in clinical trials, such as the Als3 and the Sap2 vaccines (<xref rid="B78" ref-type="bibr">78</xref>).</p><p>More recently, a study reported that a newly identified cytolytic peptide toxin, Candidalysin, is secreted from <italic toggle="yes">C. albicans</italic> to induce epithelial cell damage and inflammation and to facilitate tissue invasion (<xref rid="B128" ref-type="bibr">128</xref>). Intriguingly, the mechanism of action of this novel virulence factor is partially uncoupled from the hyphal morphogenesis program, suggesting that a vaccine targeting both the former and the latter would be more effective than one targeting only one or the other. In general, as more knowledge is gained on the pathogenesis of <italic toggle="yes">C. albicans</italic>, further targets could be added to the list of antigens to be included in a multivalent formulation. At the same time, we can also predict that as the complexity of the vaccine increases, so will regulatory hurdles and manufacturing challenges. Nevertheless, testing the efficacy and safety of a combination of more and more antigens is likely going to be crucial for better vaccines against <italic toggle="yes">Candida</italic> infections.</p></sec><sec id="S4-2"><title>Trained Immunity&#8212;Toward the Next Generation of Vaccines?</title><p>The classic vaccination paradigm is based on adaptive immunity and the raising of long-lasting, protective B- and/or T-cell memory responses (<xref rid="B129" ref-type="bibr">129</xref>). As mentioned above, mounting protective antibodies or T-cell responses across different <italic toggle="yes">Candida</italic> strains and species may be challenging due to their large genetic, phenotypic and morphological variation and plasticity. In addition, the capacity to mount B- and T-memory responses may be impaired in immunocompromised or immunosuppressed patients such as HIV/AIDS or transplant recipients who are among the highest risk groups for candidiasis. Though innate immunity lacks most of the properties of classical immunological memory, various studies have demonstrated that certain vaccines induce a type of innate immune memory known as &#8220;trained immunity&#8221; (Figure <xref ref-type="fig" rid="F2">2</xref>), which is mediated by monocytes, macrophages or NK cells (<xref rid="B72" ref-type="bibr">72</xref>). For instance, BCG vaccination reduces mortality in low-birth-weight children (<xref rid="B130" ref-type="bibr">130</xref>, <xref rid="B131" ref-type="bibr">131</xref>) and vaccination against measles reduces all-cause mortality in childhood (<xref rid="B132" ref-type="bibr">132</xref>), suggesting non-specific cross-protection against other infections (<xref rid="B133" ref-type="bibr">133</xref>).</p><fig id="F2" position="float" orientation="portrait"><label>Figure 2</label><caption><p>Vaccination strategies targeting adaptive or innate immune memory. <bold>(A)</bold> Classical vaccines initially induce a slow adaptive immune response. During this primary response, however, adaptive immune memory is raised, allowing for a more rapid and stronger secondary response upon encounter of the targeted pathogen. This protection is very long-lived, but is limited to the antigens present in the vaccine. <bold>(B)</bold> Most vaccines also induce a very rapid innate immune response. During this primary response, some vaccines also &#8220;train&#8221; innate immune cells, allowing for a stronger secondary innate response against pathogens. One advantage of this innate immune memory is the non-specificity of the secondary response, which could potentially lead to broadly cross-protective vaccines. A potential disadvantage would be the relatively shorter time window of protection.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fimmu-09-00897-g002.jpg"/></fig><p>Testing whether such innate memory responses could be stimulated also in adults, PBMCs obtained 2&#8201;weeks or 3&#8201;months after BCG vaccination were found to produce higher levels of pro-inflammatory cytokines such as TNF-&#945; and IL-1&#946; when restimulated <italic toggle="yes">in vitro</italic> with <italic toggle="yes">C. albicans</italic> (<xref rid="B134" ref-type="bibr">134</xref>). Such increased cytokine production capacity involved epigenetic changes mediated by increased H3K4 trimethylation in monocytes and was dependent on NOD2 and Rip2. Similarly, SCID mice vaccinated by BCG are protected against lethal <italic toggle="yes">C. albicans</italic> infection through a T and B lymphocyte-independent mechanism (<xref rid="B134" ref-type="bibr">134</xref>). Apart from the increased production of pro-inflammatory cytokines in monocytes, another study reported that BCG vaccination also enhances IL-1&#946; production in human NK cells when stimulated with <italic toggle="yes">C. albicans</italic>. BCG-induced protection against disseminated <italic toggle="yes">C. albicans</italic> infection was shown to be partially dependent on NK cells in NOD-SCID-IL2R&#947;<sup>&#8722;/&#8722;</sup> mice (<xref rid="B135" ref-type="bibr">135</xref>). These studies warrant clinical trials to test if BCG vaccination could reduce the risk of candidiasis in high-risk patients.</p><p>Consistent with what reviewed in Section &#8220;<xref ref-type="sec" rid="S2-1">Live-Attenuated Vaccines</xref>,&#8221; systemic infection of mice with an avirulent <italic toggle="yes">C. albicans</italic> strain was shown by Antonio Cassone&#8217;s group to confer protection against a subsequent challenge with a pathogenic <italic toggle="yes">C. albicans</italic> strain (<xref rid="B26" ref-type="bibr">26</xref>). The protection was shown to be non-specific, as cross-protection against <italic toggle="yes">C. tropicalis</italic> and <italic toggle="yes">Staphylococcus aureus</italic> was equally observed, and to be mediated by macrophage-like cells, as adoptive transfer of &#8220;plastic-adherent&#8221; cells was sufficient to confer protection against subsequent challenge with a virulent strain of <italic toggle="yes">C. albicans</italic>. Several years later, Mihai Netea&#8217;s group demonstrated that vaccination of both wild-type and RAG1<sup>&#8722;/&#8722;</sup> mice, but not CCR2<sup>&#8722;/&#8722;</sup> mice that lack circulating monocytes, with a sublethal dose of a virulent <italic toggle="yes">C. albicans</italic> strain similarly affords protection against reinfection with a lethal dose of the same strain, and dubbed the phenomenon &#8220;trained immunity&#8221; (<xref rid="B69" ref-type="bibr">69</xref>). Increased TNF-&#945; and IL-6 levels from the trained monocytes were induced by &#946;-glucan found in the <italic toggle="yes">C. albicans</italic> cell wall and sensed by Dectin-1 on host cells. In another study, mice trained with <italic toggle="yes">Candida</italic>-derived &#946;-glucan showed increased serum levels of TNF-&#945; and IL-6 when challenged by LPS four days later, but the response was transient and diminished after 20&#8201;days (<xref rid="B136" ref-type="bibr">136</xref>). To test the possibility of using &#946;-glucan as a vaccine or &#8220;immune trainer&#8221; in humans, a pilot study was conducted by orally administrating &#946;-glucan to healthy volunteers and subsequently testing innate immune responses in PBMCs restimulated <italic toggle="yes">in vitro</italic> with <italic toggle="yes">C. albicans</italic> (<xref rid="B137" ref-type="bibr">137</xref>). Enhanced innate immune responses as in the mouse model, however, were unfortunately not observed in this human study. This may probably be due to the solubility of &#946;-glucan and the absorbability of &#946;-glucan in the human GI tract. Further studies using different administration routes are still worth exploring, in order to establish whether &#946;-glucan could one day be used as a vaccine to induce trained immunity against subsequent <italic toggle="yes">Candida</italic> infections (Figure <xref ref-type="fig" rid="F2">2</xref>).</p></sec></sec><sec id="S5"><title>Concluding Remarks</title><p>With the increasing reports of multidrug resistance in several <italic toggle="yes">Candida</italic> species, prophylactic vaccination of at-risk patients likely represents a more effective long-term measure to reduce the growing incidence of <italic toggle="yes">Candida</italic>-related infections. The main challenges faced by <italic toggle="yes">Candida</italic> vaccine developers are the large variation and plasticity of these fungi, the existence of preestablished immunological tolerance and the difficulty in raising protective memory responses in patients with impaired adaptive immunity. In addition to multivalent vaccines, we propose that future vaccine development efforts should harness the growing mechanistic understanding of trained innate immunity, which might provide not only protection against candidiasis but also potentially cross-protection against a wide range of opportunistic infections. Further research on the mechanism, efficacy, and safety of raising trained immunity especially in immunocompromised patients would pave the way toward the development of a new generation of vaccines against <italic toggle="yes">Candida</italic>-related and other nosocomial infections.</p></sec><sec id="S6"><title>Author Contributions</title><p>GT and JR-C contributed equally as first authors. GT and JR-C conducted literature review and drafted the manuscript. NP conceptualized and oversaw the study and revised the manuscript. All authors read and approved the submitted version.</p></sec><sec id="S7"><title>Conflict of Interest Statement</title><p>The authors are inventors on a patent application related to the topic of this article.</p></sec></body><back><ack><p>The authors are thankful to all authors of the cited literature for their invaluable contributions and apologize for any omissions that were due to lack of space.</p></ack><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding.</bold> This work was supported by an A*STAR Investigatorship to NP (JCO/1437a00117) and by core funding by the Singapore Immunology Network (SIgN), A*STAR.</p></fn></fn-group><fn-group><fn id="fn1"><p><sup>1</sup><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT01926028">https://www.clinicaltrials.gov/ct2/show/NCT01926028</uri> (Accessed: April 17, 2018).</p></fn><fn id="fn2"><p><sup>2</sup><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT01067131">https://www.clinicaltrials.gov/ct2/show/NCT01067131</uri> (Accessed: April 17, 2018).</p></fn></fn-group><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fishman</surname><given-names>JA</given-names></name></person-group><article-title>Infection in solid-organ transplant recipients</article-title>. <source>N Engl J Med</source> (<year>2007</year>) <volume>357</volume>:<fpage>2601</fpage>&#8211;<lpage>14</lpage>.<pub-id pub-id-type="doi">10.1056/NEJMra064928</pub-id><pub-id pub-id-type="pmid">18094380</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teoh</surname><given-names>F</given-names></name><name name-style="western"><surname>Pavelka</surname><given-names>N</given-names></name></person-group>. <article-title>How chemotherapy increases the risk of systemic candidiasis in cancer patients: current paradigm and future directions</article-title>. <source>Pathogens</source> (<year>2016</year>) <volume>5</volume>:<fpage>6</fpage>.<pub-id pub-id-type="doi">10.3390/pathogens5010006</pub-id><pub-id pub-id-type="pmid">26784236</pub-id><pub-id pub-id-type="pmcid">PMC4810127</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Menzin</surname><given-names>J</given-names></name><name name-style="western"><surname>Meyers</surname><given-names>JL</given-names></name><name name-style="western"><surname>Friedman</surname><given-names>M</given-names></name><name name-style="western"><surname>Perfect</surname><given-names>JR</given-names></name><name name-style="western"><surname>Langston</surname><given-names>AA</given-names></name><name name-style="western"><surname>Danna</surname><given-names>RP</given-names></name><etal/></person-group><article-title>Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients</article-title>. <source>Am J Health Syst Pharm</source> (<year>2009</year>) <volume>66</volume>:<fpage>1711</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.2146/ajhp080325</pub-id><pub-id pub-id-type="pmid">19767376</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pfaller</surname><given-names>MA</given-names></name><name name-style="western"><surname>Diekema</surname><given-names>DJ</given-names></name></person-group>. <article-title>Epidemiology of invasive candidiasis: a persistent public health problem</article-title>. <source>Clin Microbiol Rev</source> (<year>2007</year>) <volume>20</volume>:<fpage>133</fpage>&#8211;<lpage>63</lpage>.<pub-id pub-id-type="doi">10.1128/CMR.00029-06</pub-id><pub-id pub-id-type="pmid">17223626</pub-id><pub-id pub-id-type="pmcid">PMC1797637</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Richardson</surname><given-names>M</given-names></name><name name-style="western"><surname>Lass-Florl</surname><given-names>C</given-names></name></person-group>. <article-title>Changing epidemiology of systemic fungal infections</article-title>. <source>Clin Microbiol Infect</source> (<year>2008</year>) <volume>14</volume>(<issue>Suppl 4</issue>):<fpage>5</fpage>&#8211;<lpage>24</lpage>.<pub-id pub-id-type="doi">10.1111/j.1469-0691.2008.01978.x</pub-id><pub-id pub-id-type="pmid">18430126</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wisplinghoff</surname><given-names>H</given-names></name><name name-style="western"><surname>Bischoff</surname><given-names>T</given-names></name><name name-style="western"><surname>Tallent</surname><given-names>SM</given-names></name><name name-style="western"><surname>Seifert</surname><given-names>H</given-names></name><name name-style="western"><surname>Wenzel</surname><given-names>RP</given-names></name><name name-style="western"><surname>Edmond</surname><given-names>MB</given-names></name></person-group>. <article-title>Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study</article-title>. <source>Clin Infect Dis</source> (<year>2004</year>) <volume>39</volume>:<fpage>309</fpage>&#8211;<lpage>17</lpage>.<pub-id pub-id-type="doi">10.1086/421946</pub-id><pub-id pub-id-type="pmid">15306996</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peman</surname><given-names>J</given-names></name><name name-style="western"><surname>Canton</surname><given-names>E</given-names></name><name name-style="western"><surname>Quindos</surname><given-names>G</given-names></name><name name-style="western"><surname>Eraso</surname><given-names>E</given-names></name><name name-style="western"><surname>Alcoba</surname><given-names>J</given-names></name><name name-style="western"><surname>Guinea</surname><given-names>J</given-names></name><etal/></person-group><article-title>Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey</article-title>. <source>J Antimicrob Chemother</source> (<year>2012</year>) <volume>67</volume>:<fpage>1181</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1093/jac/dks019</pub-id><pub-id pub-id-type="pmid">22351683</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cleveland</surname><given-names>AA</given-names></name><name name-style="western"><surname>Farley</surname><given-names>MM</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>LH</given-names></name><name name-style="western"><surname>Stein</surname><given-names>B</given-names></name><name name-style="western"><surname>Hollick</surname><given-names>R</given-names></name><name name-style="western"><surname>Lockhart</surname><given-names>SR</given-names></name><etal/></person-group><article-title>Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011</article-title>. <source>Clin Infect Dis</source> (<year>2012</year>) <volume>55</volume>:<fpage>1352</fpage>&#8211;<lpage>61</lpage>.<pub-id pub-id-type="doi">10.1093/cid/cis697</pub-id><pub-id pub-id-type="pmid">22893576</pub-id><pub-id pub-id-type="pmcid">PMC4698872</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eliakim-Raz</surname><given-names>N</given-names></name><name name-style="western"><surname>Babaoff</surname><given-names>R</given-names></name><name name-style="western"><surname>Yahav</surname><given-names>D</given-names></name><name name-style="western"><surname>Yanai</surname><given-names>S</given-names></name><name name-style="western"><surname>Shaked</surname><given-names>H</given-names></name><name name-style="western"><surname>Bishara</surname><given-names>J</given-names></name></person-group>. <article-title>Epidemiology, microbiology, clinical characteristics, and outcomes of candidemia in internal medicine wards-a retrospective study</article-title>. <source>Int J Infect Dis</source> (<year>2016</year>) <volume>52</volume>:<fpage>49</fpage>&#8211;<lpage>54</lpage>.<pub-id pub-id-type="doi">10.1016/j.ijid.2016.09.018</pub-id><pub-id pub-id-type="pmid">27663909</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>GD</given-names></name><name name-style="western"><surname>Denning</surname><given-names>DW</given-names></name><name name-style="western"><surname>Gow</surname><given-names>NA</given-names></name><name name-style="western"><surname>Levitz</surname><given-names>SM</given-names></name><name name-style="western"><surname>Netea</surname><given-names>MG</given-names></name><name name-style="western"><surname>White</surname><given-names>TC</given-names></name></person-group>. <article-title>Hidden killers: human fungal infections</article-title>. <source>Sci Transl Med</source> (<year>2012</year>) <volume>4</volume>:<fpage>165rv113</fpage>.<pub-id pub-id-type="doi">10.1126/scitranslmed.3004404</pub-id><pub-id pub-id-type="pmid">23253612</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>PB</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>J</given-names></name><name name-style="western"><surname>Benjamin</surname><given-names>JD</given-names></name><name name-style="western"><surname>Fridkin</surname><given-names>SK</given-names></name><name name-style="western"><surname>Sanza</surname><given-names>LT</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>LH</given-names></name><etal/></person-group><article-title>Excess costs of hospital care associated with neonatal candidemia</article-title>. <source>Pediatr Infect Dis J</source> (<year>2007</year>) <volume>26</volume>:<fpage>197</fpage>&#8211;<lpage>200</lpage>.<pub-id pub-id-type="doi">10.1097/01.inf.0000253973.89097.c0</pub-id><pub-id pub-id-type="pmid">17484214</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pappas</surname><given-names>PG</given-names></name><name name-style="western"><surname>Kauffman</surname><given-names>CA</given-names></name><name name-style="western"><surname>Andes</surname><given-names>DR</given-names></name><name name-style="western"><surname>Clancy</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Marr</surname><given-names>KA</given-names></name><name name-style="western"><surname>Ostrosky-Zeichner</surname><given-names>L</given-names></name><etal/></person-group><article-title>Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America</article-title>. <source>Clin Infect Dis</source> (<year>2016</year>) <volume>62</volume>:<fpage>e1</fpage>&#8211;<lpage>50</lpage>.<pub-id pub-id-type="doi">10.1093/cid/civ1194</pub-id><pub-id pub-id-type="pmid">26679628</pub-id><pub-id pub-id-type="pmcid">PMC4725385</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Havlickova</surname><given-names>B</given-names></name><name name-style="western"><surname>Czaika</surname><given-names>VA</given-names></name><name name-style="western"><surname>Friedrich</surname><given-names>M</given-names></name></person-group>. <article-title>Epidemiological trends in skin mycoses worldwide</article-title>. <source>Mycoses</source> (<year>2008</year>) <volume>51</volume>(<issue>Suppl 4</issue>):<fpage>2</fpage>&#8211;<lpage>15</lpage>.<pub-id pub-id-type="doi">10.1111/j.1439-0507.2008.01606.x</pub-id><pub-id pub-id-type="pmid">18783559</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sobel</surname><given-names>JD</given-names></name></person-group>. <article-title>Vulvovaginal candidosis</article-title>. <source>Lancet</source> (<year>2007</year>) <volume>369</volume>:<fpage>1961</fpage>&#8211;<lpage>71</lpage>.<pub-id pub-id-type="doi">10.1016/S0140-6736(07)60917-9</pub-id><pub-id pub-id-type="pmid">17560449</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sobel</surname><given-names>JD</given-names></name><name name-style="western"><surname>Faro</surname><given-names>S</given-names></name><name name-style="western"><surname>Force</surname><given-names>RW</given-names></name><name name-style="western"><surname>Foxman</surname><given-names>B</given-names></name><name name-style="western"><surname>Ledger</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Nyirjesy</surname><given-names>PR</given-names></name><etal/></person-group><article-title>Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations</article-title>. <source>Am J Obstet Gynecol</source> (<year>1998</year>) <volume>178</volume>:<fpage>203</fpage>&#8211;<lpage>11</lpage>.<pub-id pub-id-type="doi">10.1016/S0002-9378(98)80001-X</pub-id><pub-id pub-id-type="pmid">9500475</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cannon</surname><given-names>RD</given-names></name><name name-style="western"><surname>Lamping</surname><given-names>E</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>AR</given-names></name><name name-style="western"><surname>Niimi</surname><given-names>K</given-names></name><name name-style="western"><surname>Baret</surname><given-names>PV</given-names></name><name name-style="western"><surname>Keniya</surname><given-names>MV</given-names></name><etal/></person-group><article-title>Efflux-mediated antifungal drug resistance</article-title>. <source>Clin Microbiol Rev</source> (<year>2009</year>) <volume>22</volume>:<fpage>291</fpage>&#8211;<lpage>321</lpage>.<pub-id pub-id-type="doi">10.1128/CMR.00051-08</pub-id><pub-id pub-id-type="pmid">19366916</pub-id><pub-id pub-id-type="pmcid">PMC2668233</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Selmecki</surname><given-names>A</given-names></name><name name-style="western"><surname>Forche</surname><given-names>A</given-names></name><name name-style="western"><surname>Berman</surname><given-names>J</given-names></name></person-group>. <article-title>Aneuploidy and isochromosome formation in drug-resistant <italic toggle="yes">Candida albicans</italic></article-title>. <source>Science</source> (<year>2006</year>) <volume>313</volume>:<fpage>367</fpage>&#8211;<lpage>70</lpage>.<pub-id pub-id-type="doi">10.1126/science.1128242</pub-id><pub-id pub-id-type="pmid">16857942</pub-id><pub-id pub-id-type="pmcid">PMC1717021</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pfaller</surname><given-names>MA</given-names></name><name name-style="western"><surname>Diekema</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Gibbs</surname><given-names>DL</given-names></name><name name-style="western"><surname>Newell</surname><given-names>VA</given-names></name><name name-style="western"><surname>Ellis</surname><given-names>D</given-names></name><name name-style="western"><surname>Tullio</surname><given-names>V</given-names></name><etal/></person-group><article-title>Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of <italic toggle="yes">Candida</italic> species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion</article-title>. <source>J Clin Microbiol</source> (<year>2010</year>) <volume>48</volume>:<fpage>1366</fpage>&#8211;<lpage>77</lpage>.<pub-id pub-id-type="doi">10.1128/JCM.02117-09</pub-id><pub-id pub-id-type="pmid">20164282</pub-id><pub-id pub-id-type="pmcid">PMC2849609</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alexander</surname><given-names>BD</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>MD</given-names></name><name name-style="western"><surname>Pfeiffer</surname><given-names>CD</given-names></name><name name-style="western"><surname>Jimenez-Ortigosa</surname><given-names>C</given-names></name><name name-style="western"><surname>Catania</surname><given-names>J</given-names></name><name name-style="western"><surname>Booker</surname><given-names>R</given-names></name><etal/></person-group><article-title>Increasing echinocandin resistance in <italic toggle="yes">Candida glabrata</italic>: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations</article-title>. <source>Clin Infect Dis</source> (<year>2013</year>) <volume>56</volume>:<fpage>1724</fpage>&#8211;<lpage>32</lpage>.<pub-id pub-id-type="doi">10.1093/cid/cit136</pub-id><pub-id pub-id-type="pmid">23487382</pub-id><pub-id pub-id-type="pmcid">PMC3658363</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reales-Calderon</surname><given-names>JA</given-names></name><name name-style="western"><surname>Molero</surname><given-names>G</given-names></name><name name-style="western"><surname>Gil</surname><given-names>C</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>JL</given-names></name></person-group>. <article-title>The fungal resistome: a risk and an opportunity for the development of novel antifungal therapies</article-title>. <source>Future Med Chem</source> (<year>2016</year>) <volume>8</volume>:<fpage>1503</fpage>&#8211;<lpage>20</lpage>.<pub-id pub-id-type="doi">10.4155/fmc-2016-0051</pub-id><pub-id pub-id-type="pmid">27485839</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fadda</surname><given-names>ME</given-names></name><name name-style="western"><surname>Podda</surname><given-names>GS</given-names></name><name name-style="western"><surname>Pisano</surname><given-names>MB</given-names></name><name name-style="western"><surname>Deplano</surname><given-names>M</given-names></name><name name-style="western"><surname>Cosentino</surname><given-names>S</given-names></name></person-group>. <article-title>Prevalence of <italic toggle="yes">Candida</italic> species in different hospital wards and their susceptibility to antifungal agents: results of a three year survey</article-title>. <source>J Prev Med Hyg</source> (<year>2008</year>) <volume>49</volume>:<fpage>69</fpage>&#8211;<lpage>74</lpage>.<pub-id pub-id-type="doi">10.15167/2421-4248/jpmh2008.49.2.119</pub-id><pub-id pub-id-type="pmid">18847180</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vermitsky</surname><given-names>JP</given-names></name><name name-style="western"><surname>Edlind</surname><given-names>TD</given-names></name></person-group>. <article-title>Azole resistance in <italic toggle="yes">Candida glabrata</italic>: coordinate upregulation of multidrug transporters and evidence for a Pdr1-like transcription factor</article-title>. <source>Antimicrob Agents Chemother</source> (<year>2004</year>) <volume>48</volume>:<fpage>3773</fpage>&#8211;<lpage>81</lpage>.<pub-id pub-id-type="doi">10.1128/AAC.48.10.3773-3781.2004</pub-id><pub-id pub-id-type="pmid">15388433</pub-id><pub-id pub-id-type="pmcid">PMC521908</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vermitsky</surname><given-names>JP</given-names></name><name name-style="western"><surname>Earhart</surname><given-names>KD</given-names></name><name name-style="western"><surname>Smith</surname><given-names>WL</given-names></name><name name-style="western"><surname>Homayouni</surname><given-names>R</given-names></name><name name-style="western"><surname>Edlind</surname><given-names>TD</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>PD</given-names></name></person-group>. <article-title>Pdr1 regulates multidrug resistance in <italic toggle="yes">Candida glabrata</italic>: gene disruption and genome-wide expression studies</article-title>. <source>Mol Microbiol</source> (<year>2006</year>) <volume>61</volume>:<fpage>704</fpage>&#8211;<lpage>22</lpage>.<pub-id pub-id-type="doi">10.1111/j.1365-2958.2006.05235.x</pub-id><pub-id pub-id-type="pmid">16803598</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Navalkele</surname><given-names>BD</given-names></name><name name-style="western"><surname>Revankar</surname><given-names>S</given-names></name><name name-style="western"><surname>Chandrasekar</surname><given-names>P</given-names></name></person-group>. <article-title><italic toggle="yes">Candida auris</italic>: a worrisome, globally emerging pathogen</article-title>. <source>Expert Rev Anti Infect Ther</source> (<year>2017</year>) <volume>15</volume>(<issue>9</issue>):<fpage>819</fpage>&#8211;<lpage>27</lpage>.<pub-id pub-id-type="doi">10.1080/14787210.2017.1364992</pub-id><pub-id pub-id-type="pmid">28783385</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Denning</surname><given-names>DW</given-names></name><name name-style="western"><surname>Perlin</surname><given-names>DS</given-names></name><name name-style="western"><surname>Muldoon</surname><given-names>EG</given-names></name><name name-style="western"><surname>Colombo</surname><given-names>AL</given-names></name><name name-style="western"><surname>Chakrabarti</surname><given-names>A</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>MD</given-names></name><etal/></person-group><article-title>Delivering on antimicrobial resistance agenda not possible without improving fungal diagnostic capabilities</article-title>. <source>Emerg Infect Dis</source> (<year>2017</year>) <volume>23</volume>:<fpage>177</fpage>&#8211;<lpage>83</lpage>.<pub-id pub-id-type="doi">10.3201/eid2302.152042</pub-id><pub-id pub-id-type="pmid">27997332</pub-id><pub-id pub-id-type="pmcid">PMC5324810</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bistoni</surname><given-names>F</given-names></name><name name-style="western"><surname>Vecchiarelli</surname><given-names>A</given-names></name><name name-style="western"><surname>Cenci</surname><given-names>E</given-names></name><name name-style="western"><surname>Puccetti</surname><given-names>P</given-names></name><name name-style="western"><surname>Marconi</surname><given-names>P</given-names></name><name name-style="western"><surname>Cassone</surname><given-names>A</given-names></name></person-group>. <article-title>Evidence for macrophage-mediated protection against lethal <italic toggle="yes">Candida albicans</italic> infection</article-title>. <source>Infect Immun</source> (<year>1986</year>) <volume>51</volume>:<fpage>668</fpage>&#8211;<lpage>74</lpage>.<pub-id pub-id-type="pmid">3943907</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/iai.51.2.668-674.1986</pub-id><pub-id pub-id-type="pmcid">PMC262402</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fernandez-Arenas</surname><given-names>E</given-names></name><name name-style="western"><surname>Molero</surname><given-names>G</given-names></name><name name-style="western"><surname>Nombela</surname><given-names>C</given-names></name><name name-style="western"><surname>Diez-Orejas</surname><given-names>R</given-names></name><name name-style="western"><surname>Gil</surname><given-names>C</given-names></name></person-group>. <article-title>Low virulent strains of <italic toggle="yes">Candida albicans</italic>: unravelling the antigens for a future vaccine</article-title>. <source>Proteomics</source> (<year>2004</year>) <volume>4</volume>:<fpage>3007</fpage>&#8211;<lpage>20</lpage>.<pub-id pub-id-type="doi">10.1002/pmic.200400929</pub-id><pub-id pub-id-type="pmid">15378749</pub-id></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martinez-Lopez</surname><given-names>R</given-names></name><name name-style="western"><surname>Nombela</surname><given-names>C</given-names></name><name name-style="western"><surname>Diez-Orejas</surname><given-names>R</given-names></name><name name-style="western"><surname>Monteoliva</surname><given-names>L</given-names></name><name name-style="western"><surname>Gil</surname><given-names>C</given-names></name></person-group>. <article-title>Immunoproteomic analysis of the protective response obtained from vaccination with <italic toggle="yes">Candida albicans</italic> ecm33 cell wall mutant in mice</article-title>. <source>Proteomics</source> (<year>2008</year>) <volume>8</volume>:<fpage>2651</fpage>&#8211;<lpage>64</lpage>.<pub-id pub-id-type="doi">10.1002/pmic.200701056</pub-id><pub-id pub-id-type="pmid">18546157</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saville</surname><given-names>SP</given-names></name><name name-style="western"><surname>Lazzell</surname><given-names>AL</given-names></name><name name-style="western"><surname>Chaturvedi</surname><given-names>AK</given-names></name><name name-style="western"><surname>Monteagudo</surname><given-names>C</given-names></name><name name-style="western"><surname>Lopez-Ribot</surname><given-names>JL</given-names></name></person-group>. <article-title>Efficacy of a genetically engineered <italic toggle="yes">Candida albicans</italic> tet-NRG1 strain as an experimental live attenuated vaccine against hematogenously disseminated candidiasis</article-title>. <source>Clin Vaccine Immunol</source> (<year>2009</year>) <volume>16</volume>:<fpage>430</fpage>&#8211;<lpage>2</lpage>.<pub-id pub-id-type="doi">10.1128/CVI.00480-08</pub-id><pub-id pub-id-type="pmid">19144791</pub-id><pub-id pub-id-type="pmcid">PMC2650868</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>YL</given-names></name><name name-style="western"><surname>Wang</surname><given-names>CW</given-names></name><name name-style="western"><surname>Chen</surname><given-names>CT</given-names></name><name name-style="western"><surname>Wang</surname><given-names>MH</given-names></name><name name-style="western"><surname>Hsiao</surname><given-names>CF</given-names></name><name name-style="western"><surname>Lo</surname><given-names>HJ</given-names></name></person-group>. <article-title>Non-lethal <italic toggle="yes">Candida albicans</italic> cph1/cph1 efg1/efg1 mutant partially protects mice from systemic infections by lethal wild-type cells</article-title>. <source>Mycol Res</source> (<year>2009</year>) <volume>113</volume>:<fpage>388</fpage>&#8211;<lpage>90</lpage>.<pub-id pub-id-type="doi">10.1016/j.mycres.2008.11.016</pub-id><pub-id pub-id-type="pmid">19111931</pub-id></mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Capilla</surname><given-names>J</given-names></name><name name-style="western"><surname>Clemons</surname><given-names>KV</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name><name name-style="western"><surname>Levine</surname><given-names>HB</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>DA</given-names></name></person-group>. <article-title><italic toggle="yes">Saccharomyces cerevisiae</italic> as a vaccine against coccidioidomycosis</article-title>. <source>Vaccine</source> (<year>2009</year>) <volume>27</volume>:<fpage>3662</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1016/j.vaccine.2009.03.030</pub-id><pub-id pub-id-type="pmid">19464548</pub-id></mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name><name name-style="western"><surname>Capilla</surname><given-names>J</given-names></name><name name-style="western"><surname>Johansen</surname><given-names>ME</given-names></name><name name-style="western"><surname>Alvarado</surname><given-names>D</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>M</given-names></name><name name-style="western"><surname>Chen</surname><given-names>V</given-names></name><etal/></person-group><article-title><italic toggle="yes">Saccharomyces</italic> as a vaccine against systemic aspergillosis: &#8216;the friend of man&#8217; a friend again?</article-title><source>J Med Microbiol</source> (<year>2011</year>) <volume>60</volume>:<fpage>1423</fpage>&#8211;<lpage>32</lpage>.<pub-id pub-id-type="doi">10.1099/jmm.0.033290-0</pub-id><pub-id pub-id-type="pmid">21825307</pub-id></mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name><name name-style="western"><surname>Clemons</surname><given-names>KV</given-names></name><name name-style="western"><surname>Johansen</surname><given-names>ME</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>M</given-names></name><name name-style="western"><surname>Chen</surname><given-names>V</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>DA</given-names></name></person-group>. <article-title><italic toggle="yes">Saccharomyces</italic> as a vaccine against systemic candidiasis</article-title>. <source>Immunol Invest</source> (<year>2012</year>) <volume>41</volume>:<fpage>847</fpage>&#8211;<lpage>55</lpage>.<pub-id pub-id-type="doi">10.3109/08820139.2012.692418</pub-id><pub-id pub-id-type="pmid">22686468</pub-id></mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Majumder</surname><given-names>T</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name><name name-style="western"><surname>Chen</surname><given-names>V</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>M</given-names></name><name name-style="western"><surname>Alvarado</surname><given-names>D</given-names></name><name name-style="western"><surname>Clemons</surname><given-names>KV</given-names></name><etal/></person-group><article-title>Killed <italic toggle="yes">Saccharomyces cerevisiae</italic> protects against lethal challenge of <italic toggle="yes">Cryptococcus grubii</italic></article-title>. <source>Mycopathologia</source> (<year>2014</year>) <volume>178</volume>:<fpage>189</fpage>&#8211;<lpage>95</lpage>.<pub-id pub-id-type="doi">10.1007/s11046-014-9798-5</pub-id><pub-id pub-id-type="pmid">25118873</pub-id></mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spellberg</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Ibrahim</surname><given-names>AS</given-names></name><name name-style="western"><surname>Avenissian</surname><given-names>V</given-names></name><name name-style="western"><surname>Filler</surname><given-names>SG</given-names></name><name name-style="western"><surname>Myers</surname><given-names>CL</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>The anti-<italic toggle="yes">Candida albicans</italic> vaccine composed of the recombinant N terminus of Als1p reduces fungal burden and improves survival in both immunocompetent and immunocompromised mice</article-title>. <source>Infect Immun</source> (<year>2005</year>) <volume>73</volume>:<fpage>6191</fpage>&#8211;<lpage>3</lpage>.<pub-id pub-id-type="doi">10.1128/IAI.73.9.6191-6193.2005</pub-id><pub-id pub-id-type="pmid">16113347</pub-id><pub-id pub-id-type="pmcid">PMC1231102</pub-id></mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ibrahim</surname><given-names>AS</given-names></name><name name-style="western"><surname>Spellberg</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Avanesian</surname><given-names>V</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>JE</given-names><suffix>Jr</suffix></name></person-group>. <article-title>The anti-<italic toggle="yes">Candida</italic> vaccine based on the recombinant N-terminal domain of Als1p is broadly active against disseminated candidiasis</article-title>. <source>Infect Immun</source> (<year>2006</year>) <volume>74</volume>:<fpage>3039</fpage>&#8211;<lpage>41</lpage>.<pub-id pub-id-type="doi">10.1128/IAI.74.5.3039-3041.2006</pub-id><pub-id pub-id-type="pmid">16622247</pub-id><pub-id pub-id-type="pmcid">PMC1459699</pub-id></mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spellberg</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Ibrahim</surname><given-names>AS</given-names></name><name name-style="western"><surname>Avanesian</surname><given-names>V</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Myers</surname><given-names>C</given-names></name><name name-style="western"><surname>Phan</surname><given-names>QT</given-names></name><etal/></person-group><article-title>Efficacy of the anti-<italic toggle="yes">Candida</italic> rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis</article-title>. <source>J Infect Dis</source> (<year>2006</year>) <volume>194</volume>:<fpage>256</fpage>&#8211;<lpage>60</lpage>.<pub-id pub-id-type="doi">10.1086/504691</pub-id><pub-id pub-id-type="pmid">16779733</pub-id></mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>L</given-names></name><name name-style="western"><surname>Ibrahim</surname><given-names>AS</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X</given-names></name><name name-style="western"><surname>Farber</surname><given-names>JM</given-names></name><name name-style="western"><surname>Avanesian</surname><given-names>V</given-names></name><name name-style="western"><surname>Baquir</surname><given-names>B</given-names></name><etal/></person-group><article-title>Th1-Th17&#8201;cells mediate protective adaptive immunity against <italic toggle="yes">Staphylococcus aureus</italic> and <italic toggle="yes">Candida albicans</italic> infection in mice</article-title>. <source>PLoS Pathog</source> (<year>2009</year>) <volume>5</volume>:<fpage>e1000703</fpage>.<pub-id pub-id-type="doi">10.1371/journal.ppat.1000703</pub-id><pub-id pub-id-type="pmid">20041174</pub-id><pub-id pub-id-type="pmcid">PMC2792038</pub-id></mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmidt</surname><given-names>CS</given-names></name><name name-style="western"><surname>White</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Ibrahim</surname><given-names>AS</given-names></name><name name-style="western"><surname>Filler</surname><given-names>SG</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yeaman</surname><given-names>MR</given-names></name><etal/></person-group><article-title>NDV-3, a recombinant alum-adjuvanted vaccine for <italic toggle="yes">Candida</italic> and <italic toggle="yes">Staphylococcus aureus</italic>, is safe and immunogenic in healthy adults</article-title>. <source>Vaccine</source> (<year>2012</year>) <volume>30</volume>:<fpage>7594</fpage>&#8211;<lpage>600</lpage>.<pub-id pub-id-type="doi">10.1016/j.vaccine.2012.10.038</pub-id><pub-id pub-id-type="pmid">23099329</pub-id><pub-id pub-id-type="pmcid">PMC3513491</pub-id></mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Bernardis</surname><given-names>F</given-names></name><name name-style="western"><surname>Boccanera</surname><given-names>M</given-names></name><name name-style="western"><surname>Adriani</surname><given-names>D</given-names></name><name name-style="western"><surname>Girolamo</surname><given-names>A</given-names></name><name name-style="western"><surname>Cassone</surname><given-names>A</given-names></name></person-group>. <article-title>Intravaginal and intranasal immunizations are equally effective in inducing vaginal antibodies and conferring protection against vaginal candidiasis</article-title>. <source>Infect Immun</source> (<year>2002</year>) <volume>70</volume>:<fpage>2725</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1128/IAI.70.5.2725-2729.2002</pub-id><pub-id pub-id-type="pmid">11953420</pub-id><pub-id pub-id-type="pmcid">PMC127899</pub-id></mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Bernardis</surname><given-names>F</given-names></name><name name-style="western"><surname>Amacker</surname><given-names>M</given-names></name><name name-style="western"><surname>Arancia</surname><given-names>S</given-names></name><name name-style="western"><surname>Sandini</surname><given-names>S</given-names></name><name name-style="western"><surname>Gremion</surname><given-names>C</given-names></name><name name-style="western"><surname>Zurbriggen</surname><given-names>R</given-names></name><etal/></person-group><article-title>A virosomal vaccine against candidal vaginitis: immunogenicity, efficacy and safety profile in animal models</article-title>. <source>Vaccine</source> (<year>2012</year>) <volume>30</volume>:<fpage>4490</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1016/j.vaccine.2012.04.069</pub-id><pub-id pub-id-type="pmid">22561143</pub-id></mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Lu</surname><given-names>DN</given-names></name><name name-style="western"><surname>Gao</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Song</surname><given-names>JN</given-names></name><name name-style="western"><surname>Hua</surname><given-names>PY</given-names></name><etal/></person-group><article-title>Prophylactic vaccination with phage-displayed epitope of <italic toggle="yes">C. albicans</italic> elicits protective immune responses against systemic candidiasis in C57BL/6 mice</article-title>. <source>Vaccine</source> (<year>2005</year>) <volume>23</volume>:<fpage>4088</fpage>&#8211;<lpage>96</lpage>.<pub-id pub-id-type="doi">10.1016/j.vaccine.2004.07.005</pub-id><pub-id pub-id-type="pmid">15963364</pub-id></mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>G</given-names></name><name name-style="western"><surname>Ibrahim</surname><given-names>AS</given-names></name><name name-style="western"><surname>French</surname><given-names>SW</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>JE</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Fu</surname><given-names>Y</given-names></name></person-group>. <article-title>Active and passive immunization with rHyr1p-N protects mice against hematogenously disseminated candidiasis</article-title>. <source>PLoS One</source> (<year>2011</year>) <volume>6</volume>:<fpage>e25909</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0025909</pub-id><pub-id pub-id-type="pmid">22028796</pub-id><pub-id pub-id-type="pmcid">PMC3189951</pub-id></mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thomas</surname><given-names>DP</given-names></name><name name-style="western"><surname>Viudes</surname><given-names>A</given-names></name><name name-style="western"><surname>Monteagudo</surname><given-names>C</given-names></name><name name-style="western"><surname>Lazzell</surname><given-names>AL</given-names></name><name name-style="western"><surname>Saville</surname><given-names>SP</given-names></name><name name-style="western"><surname>Lopez-Ribot</surname><given-names>JL</given-names></name></person-group>. <article-title>A proteomic-based approach for the identification of <italic toggle="yes">Candida albicans</italic> protein components present in a subunit vaccine that protects against disseminated candidiasis</article-title>. <source>Proteomics</source> (<year>2006</year>) <volume>6</volume>:<fpage>6033</fpage>&#8211;<lpage>41</lpage>.<pub-id pub-id-type="doi">10.1002/pmic.200600321</pub-id><pub-id pub-id-type="pmid">17051645</pub-id></mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xin</surname><given-names>H</given-names></name><name name-style="western"><surname>Dziadek</surname><given-names>S</given-names></name><name name-style="western"><surname>Bundle</surname><given-names>DR</given-names></name><name name-style="western"><surname>Cutler</surname><given-names>JE</given-names></name></person-group>. <article-title>Synthetic glycopeptide vaccines combining beta-mannan and peptide epitopes induce protection against candidiasis</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2008</year>) <volume>105</volume>:<fpage>13526</fpage>&#8211;<lpage>31</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.0803195105</pub-id><pub-id pub-id-type="pmid">18725625</pub-id><pub-id pub-id-type="pmcid">PMC2533223</pub-id></mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paulovicova</surname><given-names>L</given-names></name><name name-style="western"><surname>Paulovicova</surname><given-names>E</given-names></name><name name-style="western"><surname>Karelin</surname><given-names>AA</given-names></name><name name-style="western"><surname>Tsvetkov</surname><given-names>YE</given-names></name><name name-style="western"><surname>Nifantiev</surname><given-names>NE</given-names></name><name name-style="western"><surname>Bystricky</surname><given-names>S</given-names></name></person-group><article-title>Effect of branched alpha-oligomannoside structures on induction of anti-<italic toggle="yes">Candida</italic> humoral immune response</article-title>. <source>Scand J Immunol</source> (<year>2013</year>) <volume>77</volume>:<fpage>431</fpage>&#8211;<lpage>41</lpage>.<pub-id pub-id-type="doi">10.1111/sji.12044</pub-id><pub-id pub-id-type="pmid">23488735</pub-id></mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pietrella</surname><given-names>D</given-names></name><name name-style="western"><surname>Rachini</surname><given-names>A</given-names></name><name name-style="western"><surname>Torosantucci</surname><given-names>A</given-names></name><name name-style="western"><surname>Chiani</surname><given-names>P</given-names></name><name name-style="western"><surname>Brown</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Bistoni</surname><given-names>F</given-names></name><etal/></person-group><article-title>A beta-glucan-conjugate vaccine and anti-beta-glucan antibodies are effective against murine vaginal candidiasis as assessed by a novel in vivo imaging technique</article-title>. <source>Vaccine</source> (<year>2010</year>) <volume>28</volume>:<fpage>1717</fpage>&#8211;<lpage>25</lpage>.<pub-id pub-id-type="doi">10.1016/j.vaccine.2009.12.021</pub-id><pub-id pub-id-type="pmid">20038431</pub-id></mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Torosantucci</surname><given-names>A</given-names></name><name name-style="western"><surname>Bromuro</surname><given-names>C</given-names></name><name name-style="western"><surname>Chiani</surname><given-names>P</given-names></name><name name-style="western"><surname>De Bernardis</surname><given-names>F</given-names></name><name name-style="western"><surname>Berti</surname><given-names>F</given-names></name><name name-style="western"><surname>Galli</surname><given-names>C</given-names></name><etal/></person-group><article-title>A novel glyco-conjugate vaccine against fungal pathogens</article-title>. <source>J Exp Med</source> (<year>2005</year>) <volume>202</volume>:<fpage>597</fpage>&#8211;<lpage>606</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20050749</pub-id><pub-id pub-id-type="pmid">16147975</pub-id><pub-id pub-id-type="pmcid">PMC2212864</pub-id></mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>KA</given-names></name></person-group>. <article-title>Edward Jenner and the small pox vaccine</article-title>. <source>Front Immunol</source> (<year>2011</year>) <volume>2</volume>:<fpage>21</fpage>.<pub-id pub-id-type="doi">10.3389/fimmu.2011.00021</pub-id><pub-id pub-id-type="pmid">22566811</pub-id><pub-id pub-id-type="pmcid">PMC3342363</pub-id></mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lo</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Kohler</surname><given-names>JR</given-names></name><name name-style="western"><surname>Didomenico</surname><given-names>B</given-names></name><name name-style="western"><surname>Loebenberg</surname><given-names>D</given-names></name><name name-style="western"><surname>Cacciapuoti</surname><given-names>A</given-names></name><name name-style="western"><surname>Fink</surname><given-names>GR</given-names></name></person-group>. <article-title>Nonfilamentous <italic toggle="yes">C. albicans</italic> mutants are avirulent</article-title>. <source>Cell</source> (<year>1997</year>) <volume>90</volume>:<fpage>939</fpage>&#8211;<lpage>49</lpage>.<pub-id pub-id-type="doi">10.1016/S0092-8674(00)80358-X</pub-id><pub-id pub-id-type="pmid">9298905</pub-id></mixed-citation></ref><ref id="B51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoyer</surname><given-names>LL</given-names></name><name name-style="western"><surname>Cota</surname><given-names>E</given-names></name></person-group>. <article-title><italic toggle="yes">Candida albicans</italic> agglutinin-like sequence (Als) family vignettes: a review of Als protein structure and function</article-title>. <source>Front Microbiol</source> (<year>2016</year>) <volume>7</volume>:<fpage>280</fpage>.<pub-id pub-id-type="doi">10.3389/fmicb.2016.00280</pub-id><pub-id pub-id-type="pmid">27014205</pub-id><pub-id pub-id-type="pmcid">PMC4791367</pub-id></mixed-citation></ref><ref id="B52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spellberg</surname><given-names>B</given-names></name><name name-style="western"><surname>Ibrahim</surname><given-names>AS</given-names></name><name name-style="western"><surname>Yeaman</surname><given-names>MR</given-names></name><name name-style="western"><surname>Lin</surname><given-names>L</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Avanesian</surname><given-names>V</given-names></name><etal/></person-group><article-title>The antifungal vaccine derived from the recombinant N terminus of Als3p protects mice against the bacterium <italic toggle="yes">Staphylococcus aureus</italic></article-title>. <source>Infect Immun</source> (<year>2008</year>) <volume>76</volume>:<fpage>4574</fpage>&#8211;<lpage>80</lpage>.<pub-id pub-id-type="doi">10.1128/IAI.00700-08</pub-id><pub-id pub-id-type="pmid">18644876</pub-id><pub-id pub-id-type="pmcid">PMC2546811</pub-id></mixed-citation></ref><ref id="B53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bar</surname><given-names>E</given-names></name><name name-style="western"><surname>Gladiator</surname><given-names>A</given-names></name><name name-style="western"><surname>Bastidas</surname><given-names>S</given-names></name><name name-style="western"><surname>Roschitzki</surname><given-names>B</given-names></name><name name-style="western"><surname>Acha-Orbea</surname><given-names>H</given-names></name><name name-style="western"><surname>Oxenius</surname><given-names>A</given-names></name><etal/></person-group><article-title>A novel Th cell epitope of <italic toggle="yes">Candida albicans</italic> mediates protection from fungal infection</article-title>. <source>J Immunol</source> (<year>2012</year>) <volume>188</volume>:<fpage>5636</fpage>&#8211;<lpage>43</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.1200594</pub-id><pub-id pub-id-type="pmid">22529294</pub-id></mixed-citation></ref><ref id="B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hube</surname><given-names>B</given-names></name><name name-style="western"><surname>Naglik</surname><given-names>J</given-names></name></person-group><article-title><italic toggle="yes">Candida albicans</italic> proteinases: resolving the mystery of a gene family</article-title>. <source>Microbiology</source> (<year>2001</year>) <volume>147</volume>:<fpage>1997</fpage>&#8211;<lpage>2005</lpage>.<pub-id pub-id-type="doi">10.1099/00221287-147-8-1997</pub-id><pub-id pub-id-type="pmid">11495978</pub-id></mixed-citation></ref><ref id="B55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Naglik</surname><given-names>JR</given-names></name><name name-style="western"><surname>Challacombe</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Hube</surname><given-names>B</given-names></name></person-group>. <article-title><italic toggle="yes">Candida albicans</italic> secreted aspartyl proteinases in virulence and pathogenesis</article-title>. <source>Microbiol Mol Biol Rev</source> (<year>2003</year>) <volume>67</volume>:<fpage>400</fpage>&#8211;<lpage>28, table of contents</lpage>.<pub-id pub-id-type="doi">10.1128/MMBR.67.3.400-428.2003</pub-id><pub-id pub-id-type="pmid">12966142</pub-id><pub-id pub-id-type="pmcid">PMC193873</pub-id></mixed-citation></ref><ref id="B56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matthews</surname><given-names>R</given-names></name><name name-style="western"><surname>Burnie</surname><given-names>J</given-names></name></person-group>. <article-title>Cloning of a DNA sequence encoding a major fragment of the 47 kilodalton stress protein homologue of <italic toggle="yes">Candida albicans</italic></article-title>. <source>FEMS Microbiol Lett</source> (<year>1989</year>) <volume>51</volume>:<fpage>25</fpage>&#8211;<lpage>30</lpage>.<pub-id pub-id-type="doi">10.1016/0378-1097(89)90071-2</pub-id><pub-id pub-id-type="pmid">2676706</pub-id></mixed-citation></ref><ref id="B57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matthews</surname><given-names>RC</given-names></name><name name-style="western"><surname>Burnie</surname><given-names>JP</given-names></name><name name-style="western"><surname>Tabaqchali</surname><given-names>S</given-names></name></person-group>. <article-title>Isolation of immunodominant antigens from sera of patients with systemic candidiasis and characterization of serological response to <italic toggle="yes">Candida albicans</italic></article-title>. <source>J Clin Microbiol</source> (<year>1987</year>) <volume>25</volume>:<fpage>230</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">3546361</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/jcm.25.2.230-237.1987</pub-id><pub-id pub-id-type="pmcid">PMC265873</pub-id></mixed-citation></ref><ref id="B58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matthews</surname><given-names>RC</given-names></name><name name-style="western"><surname>Rigg</surname><given-names>G</given-names></name><name name-style="western"><surname>Hodgetts</surname><given-names>S</given-names></name><name name-style="western"><surname>Carter</surname><given-names>T</given-names></name><name name-style="western"><surname>Chapman</surname><given-names>C</given-names></name><name name-style="western"><surname>Gregory</surname><given-names>C</given-names></name><etal/></person-group><article-title>Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90</article-title>. <source>Antimicrob Agents Chemother</source> (<year>2003</year>) <volume>47</volume>:<fpage>2208</fpage>&#8211;<lpage>16</lpage>.<pub-id pub-id-type="doi">10.1128/AAC.47.7.2208-2216.2003</pub-id><pub-id pub-id-type="pmid">12821470</pub-id><pub-id pub-id-type="pmcid">PMC161838</pub-id></mixed-citation></ref><ref id="B59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pachl</surname><given-names>J</given-names></name><name name-style="western"><surname>Svoboda</surname><given-names>P</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>F</given-names></name><name name-style="western"><surname>Vandewoude</surname><given-names>K</given-names></name><name name-style="western"><surname>van der Hoven</surname><given-names>B</given-names></name><name name-style="western"><surname>Spronk</surname><given-names>P</given-names></name><etal/></person-group><article-title>A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis</article-title>. <source>Clin Infect Dis</source> (<year>2006</year>) <volume>42</volume>:<fpage>1404</fpage>&#8211;<lpage>13</lpage>.<pub-id pub-id-type="doi">10.1086/503428</pub-id><pub-id pub-id-type="pmid">16619152</pub-id></mixed-citation></ref><ref id="B60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Richie</surname><given-names>DL</given-names></name><name name-style="western"><surname>Ghannoum</surname><given-names>MA</given-names></name><name name-style="western"><surname>Isham</surname><given-names>N</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>KV</given-names></name><name name-style="western"><surname>Ryder</surname><given-names>NS</given-names></name></person-group>. <article-title>Nonspecific effect of Mycograb on amphotericin B MIC</article-title>. <source>Antimicrob Agents Chemother</source> (<year>2012</year>) <volume>56</volume>:<fpage>3963</fpage>&#8211;<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1128/AAC.00435-12</pub-id><pub-id pub-id-type="pmid">22508314</pub-id><pub-id pub-id-type="pmcid">PMC3393390</pub-id></mixed-citation></ref><ref id="B61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Netea</surname><given-names>MG</given-names></name><name name-style="western"><surname>Brown</surname><given-names>GD</given-names></name><name name-style="western"><surname>Kullberg</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Gow</surname><given-names>NA</given-names></name></person-group>. <article-title>An integrated model of the recognition of <italic toggle="yes">Candida albicans</italic> by the innate immune system</article-title>. <source>Nat Rev Microbiol</source> (<year>2008</year>) <volume>6</volume>:<fpage>67</fpage>&#8211;<lpage>78</lpage>.<pub-id pub-id-type="doi">10.1038/nrmicro1815</pub-id><pub-id pub-id-type="pmid">18079743</pub-id></mixed-citation></ref><ref id="B62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Netea</surname><given-names>MG</given-names></name><name name-style="western"><surname>Gow</surname><given-names>NA</given-names></name><name name-style="western"><surname>Munro</surname><given-names>CA</given-names></name><name name-style="western"><surname>Bates</surname><given-names>S</given-names></name><name name-style="western"><surname>Collins</surname><given-names>C</given-names></name><name name-style="western"><surname>Ferwerda</surname><given-names>G</given-names></name><etal/></person-group><article-title>Immune sensing of <italic toggle="yes">Candida albicans</italic> requires cooperative recognition of mannans and glucans by lectin and toll-like receptors</article-title>. <source>J Clin Invest</source> (<year>2006</year>) <volume>116</volume>:<fpage>1642</fpage>&#8211;<lpage>50</lpage>.<pub-id pub-id-type="doi">10.1172/JCI27114</pub-id><pub-id pub-id-type="pmid">16710478</pub-id><pub-id pub-id-type="pmcid">PMC1462942</pub-id></mixed-citation></ref><ref id="B63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hall</surname><given-names>RA</given-names></name><name name-style="western"><surname>Gow</surname><given-names>NA</given-names></name></person-group>. <article-title>Mannosylation in <italic toggle="yes">Candida albicans</italic>: role in cell wall function and immune recognition</article-title>. <source>Mol Microbiol</source> (<year>2013</year>) <volume>90</volume>:<fpage>1147</fpage>&#8211;<lpage>61</lpage>.<pub-id pub-id-type="doi">10.1111/mmi.12426</pub-id><pub-id pub-id-type="pmid">24125554</pub-id><pub-id pub-id-type="pmcid">PMC4112839</pub-id></mixed-citation></ref><ref id="B64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nelson</surname><given-names>RD</given-names></name><name name-style="western"><surname>Shibata</surname><given-names>N</given-names></name><name name-style="western"><surname>Podzorski</surname><given-names>RP</given-names></name><name name-style="western"><surname>Herron</surname><given-names>MJ</given-names></name></person-group>. <article-title><italic toggle="yes">Candida</italic> mannan: chemistry, suppression of cell-mediated immunity, and possible mechanisms of action</article-title>. <source>Clin Microbiol Rev</source> (<year>1991</year>) <volume>4</volume>:<fpage>1</fpage>&#8211;<lpage>19</lpage>.<pub-id pub-id-type="doi">10.1128/CMR.4.1.1</pub-id><pub-id pub-id-type="pmid">2004345</pub-id><pub-id pub-id-type="pmcid">PMC358175</pub-id></mixed-citation></ref><ref id="B65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>MC</given-names></name><name name-style="western"><surname>Mommaas</surname><given-names>AM</given-names></name><name name-style="western"><surname>Drijfhout</surname><given-names>JW</given-names></name><name name-style="western"><surname>Jordens</surname><given-names>R</given-names></name><name name-style="western"><surname>Onderwater</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Verwoerd</surname><given-names>D</given-names></name><etal/></person-group><article-title>Mannose receptor-mediated uptake of antigens strongly enhances HLA class II-restricted antigen presentation by cultured dendritic cells</article-title>. <source>Eur J Immunol</source> (<year>1997</year>) <volume>27</volume>:<fpage>2426</fpage>&#8211;<lpage>35</lpage>.<pub-id pub-id-type="doi">10.1002/eji.1830270942</pub-id><pub-id pub-id-type="pmid">9341789</pub-id></mixed-citation></ref><ref id="B66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paulovicova</surname><given-names>L</given-names></name><name name-style="western"><surname>Paulovicova</surname><given-names>E</given-names></name><name name-style="western"><surname>Karelin</surname><given-names>AA</given-names></name><name name-style="western"><surname>Tsvetkov</surname><given-names>YE</given-names></name><name name-style="western"><surname>Nifantiev</surname><given-names>NE</given-names></name><name name-style="western"><surname>Bystricky</surname><given-names>S</given-names></name></person-group><article-title>Immune cell response to <italic toggle="yes">Candida</italic> cell wall mannan derived branched alpha-oligomannoside conjugates in mice</article-title>. <source>J Microbiol Immunol Infect</source> (<year>2015</year>) <volume>48</volume>:<fpage>9</fpage>&#8211;<lpage>19</lpage>.<pub-id pub-id-type="doi">10.1016/j.jmii.2013.08.020</pub-id><pub-id pub-id-type="pmid">24239417</pub-id></mixed-citation></ref><ref id="B67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Douglas</surname><given-names>CM</given-names></name><name name-style="western"><surname>D&#8217;ippolito</surname><given-names>JA</given-names></name><name name-style="western"><surname>Shei</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Meinz</surname><given-names>M</given-names></name><name name-style="western"><surname>Onishi</surname><given-names>J</given-names></name><name name-style="western"><surname>Marrinan</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Identification of the FKS1 gene of <italic toggle="yes">Candida albicans</italic> as the essential target of 1,3-beta-<sc>d</sc>-glucan synthase inhibitors</article-title>. <source>Antimicrob Agents Chemother</source> (<year>1997</year>) <volume>41</volume>:<fpage>2471</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">9371352</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/aac.41.11.2471</pub-id><pub-id pub-id-type="pmcid">PMC164147</pub-id></mixed-citation></ref><ref id="B68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taylor</surname><given-names>PR</given-names></name><name name-style="western"><surname>Tsoni</surname><given-names>SV</given-names></name><name name-style="western"><surname>Willment</surname><given-names>JA</given-names></name><name name-style="western"><surname>Dennehy</surname><given-names>KM</given-names></name><name name-style="western"><surname>Rosas</surname><given-names>M</given-names></name><name name-style="western"><surname>Findon</surname><given-names>H</given-names></name><etal/></person-group><article-title>Dectin-1 is required for beta-glucan recognition and control of fungal infection</article-title>. <source>Nat Immunol</source> (<year>2007</year>) <volume>8</volume>:<fpage>31</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1038/ni1408</pub-id><pub-id pub-id-type="pmid">17159984</pub-id><pub-id pub-id-type="pmcid">PMC1888731</pub-id></mixed-citation></ref><ref id="B69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quintin</surname><given-names>J</given-names></name><name name-style="western"><surname>Saeed</surname><given-names>S</given-names></name><name name-style="western"><surname>Martens</surname><given-names>JHA</given-names></name><name name-style="western"><surname>Giamarellos-Bourboulis</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Ifrim</surname><given-names>DC</given-names></name><name name-style="western"><surname>Logie</surname><given-names>C</given-names></name><etal/></person-group><article-title><italic toggle="yes">Candida albicans</italic> infection affords protection against reinfection via functional reprogramming of monocytes</article-title>. <source>Cell Host Microbe</source> (<year>2012</year>) <volume>12</volume>:<fpage>223</fpage>&#8211;<lpage>32</lpage>.<pub-id pub-id-type="doi">10.1016/j.chom.2012.06.006</pub-id><pub-id pub-id-type="pmid">22901542</pub-id><pub-id pub-id-type="pmcid">PMC3864037</pub-id></mixed-citation></ref><ref id="B70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>SC</given-names></name><name name-style="western"><surname>Quintin</surname><given-names>J</given-names></name><name name-style="western"><surname>Cramer</surname><given-names>RA</given-names></name><name name-style="western"><surname>Shepardson</surname><given-names>KM</given-names></name><name name-style="western"><surname>Saeed</surname><given-names>S</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>V</given-names></name><etal/></person-group><article-title>mTOR- and HIF-1alpha-mediated aerobic glycolysis as metabolic basis for trained immunity</article-title>. <source>Science</source> (<year>2014</year>) <volume>345</volume>:<fpage>1250684</fpage><pub-id pub-id-type="doi">10.1126/science.1250684</pub-id><pub-id pub-id-type="pmid">25258083</pub-id><pub-id pub-id-type="pmcid">PMC4226238</pub-id></mixed-citation></ref><ref id="B71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saeed</surname><given-names>S</given-names></name><name name-style="western"><surname>Quintin</surname><given-names>J</given-names></name><name name-style="western"><surname>Kerstens</surname><given-names>HH</given-names></name><name name-style="western"><surname>Rao</surname><given-names>NA</given-names></name><name name-style="western"><surname>Aghajanirefah</surname><given-names>A</given-names></name><name name-style="western"><surname>Matarese</surname><given-names>F</given-names></name><etal/></person-group><article-title>Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity</article-title>. <source>Science</source> (<year>2014</year>) <volume>345</volume>:<fpage>1251086</fpage>.<pub-id pub-id-type="doi">10.1126/science.1251086</pub-id><pub-id pub-id-type="pmid">25258085</pub-id><pub-id pub-id-type="pmcid">PMC4242194</pub-id></mixed-citation></ref><ref id="B72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Netea</surname><given-names>MG</given-names></name><name name-style="western"><surname>Joosten</surname><given-names>LA</given-names></name><name name-style="western"><surname>Latz</surname><given-names>E</given-names></name><name name-style="western"><surname>Mills</surname><given-names>KH</given-names></name><name name-style="western"><surname>Natoli</surname><given-names>G</given-names></name><name name-style="western"><surname>Stunnenberg</surname><given-names>HG</given-names></name><etal/></person-group><article-title>Trained immunity: a program of innate immune memory in health and disease</article-title>. <source>Science</source> (<year>2016</year>) <volume>352</volume>:<fpage>aaf1098</fpage>.<pub-id pub-id-type="doi">10.1126/science.aaf1098</pub-id><pub-id pub-id-type="pmid">27102489</pub-id><pub-id pub-id-type="pmcid">PMC5087274</pub-id></mixed-citation></ref><ref id="B73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bromuro</surname><given-names>C</given-names></name><name name-style="western"><surname>Romano</surname><given-names>M</given-names></name><name name-style="western"><surname>Chiani</surname><given-names>P</given-names></name><name name-style="western"><surname>Berti</surname><given-names>F</given-names></name><name name-style="western"><surname>Tontini</surname><given-names>M</given-names></name><name name-style="western"><surname>Proietti</surname><given-names>D</given-names></name><etal/></person-group><article-title>Beta-glucan-CRM197 conjugates as candidates antifungal vaccines</article-title>. <source>Vaccine</source> (<year>2010</year>) <volume>28</volume>:<fpage>2615</fpage>&#8211;<lpage>23</lpage>.<pub-id pub-id-type="doi">10.1016/j.vaccine.2010.01.012</pub-id><pub-id pub-id-type="pmid">20096763</pub-id></mixed-citation></ref><ref id="B74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sem</surname><given-names>X</given-names></name><name name-style="western"><surname>Le</surname><given-names>GT</given-names></name><name name-style="western"><surname>Tan</surname><given-names>AS</given-names></name><name name-style="western"><surname>Tso</surname><given-names>G</given-names></name><name name-style="western"><surname>Yurieva</surname><given-names>M</given-names></name><name name-style="western"><surname>Liao</surname><given-names>WW</given-names></name><etal/></person-group><article-title>Beta-glucan exposure on the fungal cell wall tightly correlates with competitive fitness of <italic toggle="yes">Candida</italic> species in the mouse gastrointestinal tract</article-title>. <source>Front Cell Infect Microbiol</source> (<year>2016</year>) <volume>6</volume>:<fpage>186</fpage><pub-id pub-id-type="doi">10.3389/fcimb.2016.00186</pub-id><pub-id pub-id-type="pmid">28066722</pub-id><pub-id pub-id-type="pmcid">PMC5177745</pub-id></mixed-citation></ref><ref id="B75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barnett</surname><given-names>JA</given-names></name></person-group><article-title>A history of research on yeasts 12: medical yeasts part 1, <italic toggle="yes">Candida albicans</italic></article-title>. <source>Yeast</source> (<year>2008</year>) <volume>25</volume>:<fpage>385</fpage>&#8211;<lpage>417</lpage>.<pub-id pub-id-type="doi">10.1002/yea.1595</pub-id><pub-id pub-id-type="pmid">18509848</pub-id></mixed-citation></ref><ref id="B76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fujimura</surname><given-names>KE</given-names></name><name name-style="western"><surname>Sitarik</surname><given-names>AR</given-names></name><name name-style="western"><surname>Havstad</surname><given-names>S</given-names></name><name name-style="western"><surname>Lin</surname><given-names>DL</given-names></name><name name-style="western"><surname>Levan</surname><given-names>S</given-names></name><name name-style="western"><surname>Fadrosh</surname><given-names>D</given-names></name><etal/></person-group><article-title>Neonatal gut microbiota associates with childhood multisensitized atopy and T cell differentiation</article-title>. <source>Nat Med</source> (<year>2016</year>) <volume>22</volume>:<fpage>1187</fpage>&#8211;<lpage>91</lpage>.<pub-id pub-id-type="doi">10.1038/nm.4176</pub-id><pub-id pub-id-type="pmid">27618652</pub-id><pub-id pub-id-type="pmcid">PMC5053876</pub-id></mixed-citation></ref><ref id="B77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bougnoux</surname><given-names>ME</given-names></name><name name-style="western"><surname>Diogo</surname><given-names>D</given-names></name><name name-style="western"><surname>Francois</surname><given-names>N</given-names></name><name name-style="western"><surname>Sendid</surname><given-names>B</given-names></name><name name-style="western"><surname>Veirmeire</surname><given-names>S</given-names></name><name name-style="western"><surname>Colombel</surname><given-names>JF</given-names></name><etal/></person-group><article-title>Multilocus sequence typing reveals intrafamilial transmission and microevolutions of <italic toggle="yes">Candida albicans</italic> isolates from the human digestive tract</article-title>. <source>J Clin Microbiol</source> (<year>2006</year>) <volume>44</volume>:<fpage>1810</fpage>&#8211;<lpage>20</lpage>.<pub-id pub-id-type="doi">10.1128/JCM.44.5.1810-1820.2006</pub-id><pub-id pub-id-type="pmid">16672411</pub-id><pub-id pub-id-type="pmcid">PMC1479199</pub-id></mixed-citation></ref><ref id="B78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cassone</surname><given-names>A</given-names></name></person-group>. <article-title>Development of vaccines for <italic toggle="yes">Candida albicans</italic>: fighting a skilled transformer</article-title>. <source>Nat Rev Microbiol</source> (<year>2013</year>) <volume>11</volume>:<fpage>884</fpage>&#8211;<lpage>91</lpage>.<pub-id pub-id-type="doi">10.1038/nrmicro3156</pub-id><pub-id pub-id-type="pmid">24232568</pub-id></mixed-citation></ref><ref id="B79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carvalho</surname><given-names>A</given-names></name><name name-style="western"><surname>Cunha</surname><given-names>C</given-names></name><name name-style="western"><surname>Bozza</surname><given-names>S</given-names></name><name name-style="western"><surname>Moretti</surname><given-names>S</given-names></name><name name-style="western"><surname>Massi-Benedetti</surname><given-names>C</given-names></name><name name-style="western"><surname>Bistoni</surname><given-names>F</given-names></name><etal/></person-group><article-title>Immunity and tolerance to fungi in hematopoietic transplantation: principles and perspectives</article-title>. <source>Front Immunol</source> (<year>2012</year>) <volume>3</volume>:<fpage>156</fpage>.<pub-id pub-id-type="doi">10.3389/fimmu.2012.00156</pub-id><pub-id pub-id-type="pmid">22707953</pub-id><pub-id pub-id-type="pmcid">PMC3374351</pub-id></mixed-citation></ref><ref id="B80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumamoto</surname><given-names>CA</given-names></name><name name-style="western"><surname>Vinces</surname><given-names>MD</given-names></name></person-group>. <article-title>Contributions of hyphae and hypha-co-regulated genes to <italic toggle="yes">Candida albicans</italic> virulence</article-title>. <source>Cell Microbiol</source> (<year>2005</year>) <volume>7</volume>:<fpage>1546</fpage>&#8211;<lpage>54</lpage>.<pub-id pub-id-type="doi">10.1111/j.1462-5822.2005.00616.x</pub-id><pub-id pub-id-type="pmid">16207242</pub-id></mixed-citation></ref><ref id="B81"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miranda</surname><given-names>LN</given-names></name><name name-style="western"><surname>van der Heijden</surname><given-names>IM</given-names></name><name name-style="western"><surname>Costa</surname><given-names>SF</given-names></name><name name-style="western"><surname>Sousa</surname><given-names>AP</given-names></name><name name-style="western"><surname>Sienra</surname><given-names>RA</given-names></name><name name-style="western"><surname>Gobara</surname><given-names>S</given-names></name><etal/></person-group><article-title><italic toggle="yes">Candida</italic> colonisation as a source for candidaemia</article-title>. <source>J Hosp Infect</source> (<year>2009</year>) <volume>72</volume>:<fpage>9</fpage>&#8211;<lpage>16</lpage>.<pub-id pub-id-type="doi">10.1016/j.jhin.2009.02.009</pub-id><pub-id pub-id-type="pmid">19303662</pub-id></mixed-citation></ref><ref id="B82"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koh</surname><given-names>AY</given-names></name><name name-style="western"><surname>Kohler</surname><given-names>JR</given-names></name><name name-style="western"><surname>Coggshall</surname><given-names>KT</given-names></name><name name-style="western"><surname>Van Rooijen</surname><given-names>N</given-names></name><name name-style="western"><surname>Pier</surname><given-names>GB</given-names></name></person-group>. <article-title>Mucosal damage and neutropenia are required for <italic toggle="yes">Candida albicans</italic> dissemination</article-title>. <source>PLoS Pathog</source> (<year>2008</year>) <volume>4</volume>:<fpage>e35</fpage>.<pub-id pub-id-type="doi">10.1371/journal.ppat.0040035</pub-id><pub-id pub-id-type="pmid">18282097</pub-id><pub-id pub-id-type="pmcid">PMC2242836</pub-id></mixed-citation></ref><ref id="B83"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heilmann</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Sorgo</surname><given-names>AG</given-names></name><name name-style="western"><surname>Siliakus</surname><given-names>AR</given-names></name><name name-style="western"><surname>Dekker</surname><given-names>HL</given-names></name><name name-style="western"><surname>Brul</surname><given-names>S</given-names></name><name name-style="western"><surname>De Koster</surname><given-names>CG</given-names></name><etal/></person-group><article-title>Hyphal induction in the human fungal pathogen <italic toggle="yes">Candida albicans</italic> reveals a characteristic wall protein profile</article-title>. <source>Microbiology</source> (<year>2011</year>) <volume>157</volume>:<fpage>2297</fpage>&#8211;<lpage>307</lpage>.<pub-id pub-id-type="doi">10.1099/mic.0.049395-0</pub-id><pub-id pub-id-type="pmid">21602216</pub-id></mixed-citation></ref><ref id="B84"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saville</surname><given-names>SP</given-names></name><name name-style="western"><surname>Lazzell</surname><given-names>AL</given-names></name><name name-style="western"><surname>Monteagudo</surname><given-names>C</given-names></name><name name-style="western"><surname>Lopez-Ribot</surname><given-names>JL</given-names></name></person-group>. <article-title>Engineered control of cell morphology in vivo reveals distinct roles for yeast and filamentous forms of <italic toggle="yes">Candida albicans</italic> during infection</article-title>. <source>Eukaryot Cell</source> (<year>2003</year>) <volume>2</volume>:<fpage>1053</fpage>&#8211;<lpage>60</lpage>.<pub-id pub-id-type="doi">10.1128/EC.2.5.1053-1060.2003</pub-id><pub-id pub-id-type="pmid">14555488</pub-id><pub-id pub-id-type="pmcid">PMC219382</pub-id></mixed-citation></ref><ref id="B85"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Di Carlo</surname><given-names>P</given-names></name><name name-style="western"><surname>Di Vita</surname><given-names>G</given-names></name><name name-style="western"><surname>Guadagnino</surname><given-names>G</given-names></name><name name-style="western"><surname>Cocorullo</surname><given-names>G</given-names></name><name name-style="western"><surname>D&#8217;arpa</surname><given-names>F</given-names></name><name name-style="western"><surname>Salamone</surname><given-names>G</given-names></name><etal/></person-group><article-title>Surgical pathology and the diagnosis of invasive visceral yeast infection: two case reports and literature review</article-title>. <source>World J Emerg Surg</source> (<year>2013</year>) <volume>8</volume>:<fpage>38</fpage>.<pub-id pub-id-type="doi">10.1186/1749-7922-8-38</pub-id><pub-id pub-id-type="pmid">24067049</pub-id><pub-id pub-id-type="pmcid">PMC3849356</pub-id></mixed-citation></ref><ref id="B86"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Noble</surname><given-names>SM</given-names></name><name name-style="western"><surname>French</surname><given-names>S</given-names></name><name name-style="western"><surname>Kohn</surname><given-names>LA</given-names></name><name name-style="western"><surname>Chen</surname><given-names>V</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>AD</given-names></name></person-group>. <article-title>Systematic screens of a <italic toggle="yes">Candida albicans</italic> homozygous deletion library decouple morphogenetic switching and pathogenicity</article-title>. <source>Nat Genet</source> (<year>2010</year>) <volume>42</volume>:<fpage>590</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1038/ng.605</pub-id><pub-id pub-id-type="pmid">20543849</pub-id><pub-id pub-id-type="pmcid">PMC2893244</pub-id></mixed-citation></ref><ref id="B87"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lionakis</surname><given-names>MS</given-names></name><name name-style="western"><surname>Lim</surname><given-names>JK</given-names></name><name name-style="western"><surname>Lee</surname><given-names>CC</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>PM</given-names></name></person-group>. <article-title>Organ-specific innate immune responses in a mouse model of invasive candidiasis</article-title>. <source>J Innate Immun</source> (<year>2011</year>) <volume>3</volume>:<fpage>180</fpage>&#8211;<lpage>99</lpage>.<pub-id pub-id-type="doi">10.1159/000321157</pub-id><pub-id pub-id-type="pmid">21063074</pub-id><pub-id pub-id-type="pmcid">PMC3072204</pub-id></mixed-citation></ref><ref id="B88"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lohse</surname><given-names>MB</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>AD</given-names></name></person-group>. <article-title>White-opaque switching in <italic toggle="yes">Candida albicans</italic></article-title>. <source>Curr Opin Microbiol</source> (<year>2009</year>) <volume>12</volume>:<fpage>650</fpage>&#8211;<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1016/j.mib.2009.09.010</pub-id><pub-id pub-id-type="pmid">19853498</pub-id><pub-id pub-id-type="pmcid">PMC2812476</pub-id></mixed-citation></ref><ref id="B89"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kvaal</surname><given-names>CA</given-names></name><name name-style="western"><surname>Srikantha</surname><given-names>T</given-names></name><name name-style="western"><surname>Soll</surname><given-names>DR</given-names></name></person-group>. <article-title>Misexpression of the white-phase-specific gene WH11 in the opaque phase of <italic toggle="yes">Candida albicans</italic> affects switching and virulence</article-title>. <source>Infect Immun</source> (<year>1997</year>) <volume>65</volume>:<fpage>4468</fpage>&#8211;<lpage>75</lpage>.<pub-id pub-id-type="pmid">9353021</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/iai.65.11.4468-4475.1997</pub-id><pub-id pub-id-type="pmcid">PMC175642</pub-id></mixed-citation></ref><ref id="B90"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kvaal</surname><given-names>C</given-names></name><name name-style="western"><surname>Lachke</surname><given-names>SA</given-names></name><name name-style="western"><surname>Srikantha</surname><given-names>T</given-names></name><name name-style="western"><surname>Daniels</surname><given-names>K</given-names></name><name name-style="western"><surname>Mccoy</surname><given-names>J</given-names></name><name name-style="western"><surname>Soll</surname><given-names>DR</given-names></name></person-group>. <article-title>Misexpression of the opaque-phase-specific gene PEP1 (SAP1) in the white phase of <italic toggle="yes">Candida albicans</italic> confers increased virulence in a mouse model of cutaneous infection</article-title>. <source>Infect Immun</source> (<year>1999</year>) <volume>67</volume>:<fpage>6652</fpage>&#8211;<lpage>62</lpage>.<pub-id pub-id-type="pmid">10569787</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/iai.67.12.6652-6662.1999</pub-id><pub-id pub-id-type="pmcid">PMC97079</pub-id></mixed-citation></ref><ref id="B91"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Si</surname><given-names>H</given-names></name><name name-style="western"><surname>Hernday</surname><given-names>AD</given-names></name><name name-style="western"><surname>Hirakawa</surname><given-names>MP</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>AD</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>RJ</given-names></name></person-group>. <article-title><italic toggle="yes">Candida albicans</italic> white and opaque cells undergo distinct programs of filamentous growth</article-title>. <source>PLoS Pathog</source> (<year>2013</year>) <volume>9</volume>:<fpage>e1003210</fpage>.<pub-id pub-id-type="doi">10.1371/journal.ppat.1003210</pub-id><pub-id pub-id-type="pmid">23505370</pub-id><pub-id pub-id-type="pmcid">PMC3591317</pub-id></mixed-citation></ref><ref id="B92"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lohse</surname><given-names>MB</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>AD</given-names></name></person-group>. <article-title>Differential phagocytosis of white versus opaque <italic toggle="yes">Candida albicans</italic> by <italic toggle="yes">Drosophila</italic> and mouse phagocytes</article-title>. <source>PLoS One</source> (<year>2008</year>) <volume>3</volume>:<fpage>e1473</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0001473</pub-id><pub-id pub-id-type="pmid">18213381</pub-id><pub-id pub-id-type="pmcid">PMC2198939</pub-id></mixed-citation></ref><ref id="B93"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sasse</surname><given-names>C</given-names></name><name name-style="western"><surname>Hasenberg</surname><given-names>M</given-names></name><name name-style="western"><surname>Weyler</surname><given-names>M</given-names></name><name name-style="western"><surname>Gunzer</surname><given-names>M</given-names></name><name name-style="western"><surname>Morschhauser</surname><given-names>J</given-names></name></person-group>. <article-title>White-opaque switching of <italic toggle="yes">Candida albicans</italic> allows immune evasion in an environment-dependent fashion</article-title>. <source>Eukaryot Cell</source> (<year>2013</year>) <volume>12</volume>:<fpage>50</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1128/EC.00266-12</pub-id><pub-id pub-id-type="pmid">23125350</pub-id><pub-id pub-id-type="pmcid">PMC3535852</pub-id></mixed-citation></ref><ref id="B94"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pande</surname><given-names>K</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name><name name-style="western"><surname>Noble</surname><given-names>SM</given-names></name></person-group>. <article-title>Passage through the mammalian gut triggers a phenotypic switch that promotes <italic toggle="yes">Candida albicans</italic> commensalism</article-title>. <source>Nat Genet</source> (<year>2013</year>) <volume>45</volume>:<fpage>1088</fpage>&#8211;<lpage>91</lpage>.<pub-id pub-id-type="doi">10.1038/ng.2710</pub-id><pub-id pub-id-type="pmid">23892606</pub-id><pub-id pub-id-type="pmcid">PMC3758371</pub-id></mixed-citation></ref><ref id="B95"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Selmecki</surname><given-names>A</given-names></name><name name-style="western"><surname>Forche</surname><given-names>A</given-names></name><name name-style="western"><surname>Berman</surname><given-names>J</given-names></name></person-group>. <article-title>Genomic plasticity of the human fungal pathogen <italic toggle="yes">Candida albicans</italic></article-title>. <source>Eukaryot Cell</source> (<year>2010</year>) <volume>9</volume>:<fpage>991</fpage>&#8211;<lpage>1008</lpage>.<pub-id pub-id-type="doi">10.1128/EC.00060-10</pub-id><pub-id pub-id-type="pmid">20495058</pub-id><pub-id pub-id-type="pmcid">PMC2901674</pub-id></mixed-citation></ref><ref id="B96"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Selmecki</surname><given-names>A</given-names></name><name name-style="western"><surname>Gerami-Nejad</surname><given-names>M</given-names></name><name name-style="western"><surname>Paulson</surname><given-names>C</given-names></name><name name-style="western"><surname>Forche</surname><given-names>A</given-names></name><name name-style="western"><surname>Berman</surname><given-names>J</given-names></name></person-group>. <article-title>An isochromosome confers drug resistance in vivo by amplification of two genes, ERG11 and TAC1</article-title>. <source>Mol Microbiol</source> (<year>2008</year>) <volume>68</volume>:<fpage>624</fpage>&#8211;<lpage>41</lpage>.<pub-id pub-id-type="doi">10.1111/j.1365-2958.2008.06176.x</pub-id><pub-id pub-id-type="pmid">18363649</pub-id></mixed-citation></ref><ref id="B97"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hirakawa</surname><given-names>MP</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>DA</given-names></name><name name-style="western"><surname>Sakthikumar</surname><given-names>S</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>MZ</given-names></name><name name-style="western"><surname>Berlin</surname><given-names>A</given-names></name><name name-style="western"><surname>Gujja</surname><given-names>S</given-names></name><etal/></person-group><article-title>Genetic and phenotypic intra-species variation in <italic toggle="yes">Candida albicans</italic></article-title>. <source>Genome Res</source> (<year>2015</year>) <volume>25</volume>:<fpage>413</fpage>&#8211;<lpage>25</lpage>.<pub-id pub-id-type="doi">10.1101/gr.174623.114</pub-id><pub-id pub-id-type="pmid">25504520</pub-id><pub-id pub-id-type="pmcid">PMC4352881</pub-id></mixed-citation></ref><ref id="B98"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mandelblat</surname><given-names>M</given-names></name><name name-style="western"><surname>Frenkel</surname><given-names>M</given-names></name><name name-style="western"><surname>Abbey</surname><given-names>D</given-names></name><name name-style="western"><surname>Ben Ami</surname><given-names>R</given-names></name><name name-style="western"><surname>Berman</surname><given-names>J</given-names></name><name name-style="western"><surname>Segal</surname><given-names>E</given-names></name></person-group>. <article-title>Phenotypic and genotypic characteristics of <italic toggle="yes">Candida albicans</italic> isolates from bloodstream and mucosal infections</article-title>. <source>Mycoses</source> (<year>2017</year>) <volume>60</volume>:<fpage>534</fpage>&#8211;<lpage>45</lpage>.<pub-id pub-id-type="doi">10.1111/myc.12623</pub-id><pub-id pub-id-type="pmid">28543785</pub-id></mixed-citation></ref><ref id="B99"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pfaller</surname><given-names>MA</given-names></name><name name-style="western"><surname>Diekema</surname><given-names>DJ</given-names></name></person-group>. <article-title>Epidemiology of invasive mycoses in North America</article-title>. <source>Crit Rev Microbiol</source> (<year>2010</year>) <volume>36</volume>:<fpage>1</fpage>&#8211;<lpage>53</lpage>.<pub-id pub-id-type="doi">10.3109/10408410903241444</pub-id><pub-id pub-id-type="pmid">20088682</pub-id></mixed-citation></ref><ref id="B100"><label>100</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Falagas</surname><given-names>ME</given-names></name><name name-style="western"><surname>Apostolou</surname><given-names>KE</given-names></name><name name-style="western"><surname>Pappas</surname><given-names>VD</given-names></name></person-group>. <article-title>Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies</article-title>. <source>Eur J Clin Microbiol Infect Dis</source> (<year>2006</year>) <volume>25</volume>:<fpage>419</fpage>&#8211;<lpage>25</lpage>.<pub-id pub-id-type="doi">10.1007/s10096-006-0159-2</pub-id><pub-id pub-id-type="pmid">16773391</pub-id></mixed-citation></ref><ref id="B101"><label>101</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eggimann</surname><given-names>P</given-names></name><name name-style="western"><surname>Garbino</surname><given-names>J</given-names></name><name name-style="western"><surname>Pittet</surname><given-names>D</given-names></name></person-group>. <article-title>Epidemiology of <italic toggle="yes">Candida</italic> species infections in critically ill non-immunosuppressed patients</article-title>. <source>Lancet Infect Dis</source> (<year>2003</year>) <volume>3</volume>:<fpage>685</fpage>&#8211;<lpage>702</lpage>.<pub-id pub-id-type="doi">10.1016/S1473-3099(03)00801-6</pub-id><pub-id pub-id-type="pmid">14592598</pub-id></mixed-citation></ref><ref id="B102"><label>102</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bassetti</surname><given-names>M</given-names></name><name name-style="western"><surname>Merelli</surname><given-names>M</given-names></name><name name-style="western"><surname>Righi</surname><given-names>E</given-names></name><name name-style="western"><surname>Diaz-Martin</surname><given-names>A</given-names></name><name name-style="western"><surname>Rosello</surname><given-names>EM</given-names></name><name name-style="western"><surname>Luzzati</surname><given-names>R</given-names></name><etal/></person-group><article-title>Epidemiology, species distribution, antifungal susceptibility, and outcome of candidemia across five sites in Italy and Spain</article-title>. <source>J Clin Microbiol</source> (<year>2013</year>) <volume>51</volume>:<fpage>4167</fpage>&#8211;<lpage>72</lpage>.<pub-id pub-id-type="doi">10.1128/JCM.01998-13</pub-id><pub-id pub-id-type="pmid">24108614</pub-id><pub-id pub-id-type="pmcid">PMC3838046</pub-id></mixed-citation></ref><ref id="B103"><label>103</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pfaller</surname><given-names>MA</given-names></name><name name-style="western"><surname>Castanheira</surname><given-names>M</given-names></name><name name-style="western"><surname>Messer</surname><given-names>SA</given-names></name><name name-style="western"><surname>Moet</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Jones</surname><given-names>RN</given-names></name></person-group><article-title>Variation in <italic toggle="yes">Candida</italic> spp. distribution and antifungal resistance rates among bloodstream infection isolates by patient age: report from the SENTRY Antimicrobial Surveillance Program (2008-2009)</article-title>. <source>Diagn Microbiol Infect Dis</source> (<year>2010</year>) <volume>68</volume>:<fpage>278</fpage>&#8211;<lpage>83</lpage>.<pub-id pub-id-type="doi">10.1016/j.diagmicrobio.2010.06.015</pub-id><pub-id pub-id-type="pmid">20846808</pub-id></mixed-citation></ref><ref id="B104"><label>104</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guinea</surname><given-names>J</given-names></name></person-group>. <article-title>Global trends in the distribution of <italic toggle="yes">Candida</italic> species causing candidemia</article-title>. <source>Clin Microbiol Infect</source> (<year>2014</year>) <volume>20</volume>(<issue>Suppl 6</issue>):<fpage>5</fpage>&#8211;<lpage>10</lpage>.<pub-id pub-id-type="doi">10.1111/1469-0691.12539</pub-id><pub-id pub-id-type="pmid">24506442</pub-id></mixed-citation></ref><ref id="B105"><label>105</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trofa</surname><given-names>D</given-names></name><name name-style="western"><surname>Gacser</surname><given-names>A</given-names></name><name name-style="western"><surname>Nosanchuk</surname><given-names>JD</given-names></name></person-group>. <article-title><italic toggle="yes">Candida</italic> parapsilosis, an emerging fungal pathogen</article-title>. <source>Clin Microbiol Rev</source> (<year>2008</year>) <volume>21</volume>:<fpage>606</fpage>&#8211;<lpage>25</lpage>.<pub-id pub-id-type="doi">10.1128/CMR.00013-08</pub-id><pub-id pub-id-type="pmid">18854483</pub-id><pub-id pub-id-type="pmcid">PMC2570155</pub-id></mixed-citation></ref><ref id="B106"><label>106</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nucci</surname><given-names>M</given-names></name><name name-style="western"><surname>Colombo</surname><given-names>AL</given-names></name></person-group>. <article-title>Candidemia due to <italic toggle="yes">Candida tropicalis</italic>: clinical, epidemiologic, and microbiologic characteristics of 188 episodes occurring in tertiary care hospitals</article-title>. <source>Diagn Microbiol Infect Dis</source> (<year>2007</year>) <volume>58</volume>:<fpage>77</fpage>&#8211;<lpage>82</lpage>.<pub-id pub-id-type="doi">10.1016/j.diagmicrobio.2006.11.009</pub-id><pub-id pub-id-type="pmid">17368800</pub-id></mixed-citation></ref><ref id="B107"><label>107</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spivak</surname><given-names>ES</given-names></name><name name-style="western"><surname>Hanson</surname><given-names>KE</given-names></name></person-group>. <article-title><italic toggle="yes">Candida auris</italic>: an emerging fungal pathogen</article-title>. <source>J Clin Microbiol</source> (<year>2018</year>) <volume>56</volume>:<fpage>e01588-17</fpage>.<pub-id pub-id-type="doi">10.1128/JCM.01588-17</pub-id><pub-id pub-id-type="pmid">29167291</pub-id><pub-id pub-id-type="pmcid">PMC5786713</pub-id></mixed-citation></ref><ref id="B108"><label>108</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nace</surname><given-names>HL</given-names></name><name name-style="western"><surname>Horn</surname><given-names>D</given-names></name><name name-style="western"><surname>Neofytos</surname><given-names>D</given-names></name></person-group>. <article-title>Epidemiology and outcome of multiple-species candidemia at a tertiary care center between 2004 and 2007</article-title>. <source>Diagn Microbiol Infect Dis</source> (<year>2009</year>) <volume>64</volume>:<fpage>289</fpage>&#8211;<lpage>94</lpage>.<pub-id pub-id-type="doi">10.1016/j.diagmicrobio.2009.03.010</pub-id><pub-id pub-id-type="pmid">19376670</pub-id></mixed-citation></ref><ref id="B109"><label>109</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nutsch</surname><given-names>KM</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>CS</given-names></name></person-group>. <article-title>T cell tolerance and immunity to commensal bacteria</article-title>. <source>Curr Opin Immunol</source> (<year>2012</year>) <volume>24</volume>:<fpage>385</fpage>&#8211;<lpage>91</lpage>.<pub-id pub-id-type="doi">10.1016/j.coi.2012.04.009</pub-id><pub-id pub-id-type="pmid">22613090</pub-id><pub-id pub-id-type="pmcid">PMC3423487</pub-id></mixed-citation></ref><ref id="B110"><label>110</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Round</surname><given-names>JL</given-names></name><name name-style="western"><surname>Mazmanian</surname><given-names>SK</given-names></name></person-group>. <article-title>Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2010</year>) <volume>107</volume>:<fpage>12204</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.0909122107</pub-id><pub-id pub-id-type="pmid">20566854</pub-id><pub-id pub-id-type="pmcid">PMC2901479</pub-id></mixed-citation></ref><ref id="B111"><label>111</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Atarashi</surname><given-names>K</given-names></name><name name-style="western"><surname>Tanoue</surname><given-names>T</given-names></name><name name-style="western"><surname>Oshima</surname><given-names>K</given-names></name><name name-style="western"><surname>Suda</surname><given-names>W</given-names></name><name name-style="western"><surname>Nagano</surname><given-names>Y</given-names></name><name name-style="western"><surname>Nishikawa</surname><given-names>H</given-names></name><etal/></person-group><article-title>Treg induction by a rationally selected mixture of clostridia strains from the human microbiota</article-title>. <source>Nature</source> (<year>2013</year>) <volume>500</volume>:<fpage>232</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1038/nature12331</pub-id><pub-id pub-id-type="pmid">23842501</pub-id></mixed-citation></ref><ref id="B112"><label>112</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Furusawa</surname><given-names>Y</given-names></name><name name-style="western"><surname>Obata</surname><given-names>Y</given-names></name><name name-style="western"><surname>Fukuda</surname><given-names>S</given-names></name><name name-style="western"><surname>Endo</surname><given-names>TA</given-names></name><name name-style="western"><surname>Nakato</surname><given-names>G</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>D</given-names></name><etal/></person-group><article-title>Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells</article-title>. <source>Nature</source> (<year>2013</year>) <volume>504</volume>:<fpage>446</fpage>&#8211;<lpage>50</lpage>.<pub-id pub-id-type="doi">10.1038/nature12721</pub-id><pub-id pub-id-type="pmid">24226770</pub-id></mixed-citation></ref><ref id="B113"><label>113</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zelante</surname><given-names>T</given-names></name><name name-style="western"><surname>Iannitti</surname><given-names>RG</given-names></name><name name-style="western"><surname>Cunha</surname><given-names>C</given-names></name><name name-style="western"><surname>De Luca</surname><given-names>A</given-names></name><name name-style="western"><surname>Giovannini</surname><given-names>G</given-names></name><name name-style="western"><surname>Pieraccini</surname><given-names>G</given-names></name><etal/></person-group><article-title>Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22</article-title>. <source>Immunity</source> (<year>2013</year>) <volume>39</volume>:<fpage>372</fpage>&#8211;<lpage>85</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2013.08.003</pub-id><pub-id pub-id-type="pmid">23973224</pub-id></mixed-citation></ref><ref id="B114"><label>114</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Romani</surname><given-names>L</given-names></name><name name-style="western"><surname>Zelante</surname><given-names>T</given-names></name><name name-style="western"><surname>De Luca</surname><given-names>A</given-names></name><name name-style="western"><surname>Iannitti</surname><given-names>RG</given-names></name><name name-style="western"><surname>Moretti</surname><given-names>S</given-names></name><name name-style="western"><surname>Bartoli</surname><given-names>A</given-names></name><etal/></person-group><article-title>Microbiota control of a tryptophan-AhR pathway in disease tolerance to fungi</article-title>. <source>Eur J Immunol</source> (<year>2014</year>) <volume>44</volume>:<fpage>3192</fpage>&#8211;<lpage>200</lpage>.<pub-id pub-id-type="doi">10.1002/eji.201344406</pub-id><pub-id pub-id-type="pmid">25256754</pub-id></mixed-citation></ref><ref id="B115"><label>115</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonifazi</surname><given-names>P</given-names></name><name name-style="western"><surname>Zelante</surname><given-names>T</given-names></name><name name-style="western"><surname>D&#8217;angelo</surname><given-names>C</given-names></name><name name-style="western"><surname>De Luca</surname><given-names>A</given-names></name><name name-style="western"><surname>Moretti</surname><given-names>S</given-names></name><name name-style="western"><surname>Bozza</surname><given-names>S</given-names></name><etal/></person-group><article-title>Balancing inflammation and tolerance in vivo through dendritic cells by the commensal <italic toggle="yes">Candida albicans</italic></article-title>. <source>Mucosal Immunol</source> (<year>2009</year>) <volume>2</volume>:<fpage>362</fpage>&#8211;<lpage>74</lpage>.<pub-id pub-id-type="doi">10.1038/mi.2009.17</pub-id><pub-id pub-id-type="pmid">19421183</pub-id></mixed-citation></ref><ref id="B116"><label>116</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duggan</surname><given-names>S</given-names></name><name name-style="western"><surname>Leonhardt</surname><given-names>I</given-names></name><name name-style="western"><surname>Hunniger</surname><given-names>K</given-names></name><name name-style="western"><surname>Kurzai</surname><given-names>O</given-names></name></person-group>. <article-title>Host response to <italic toggle="yes">Candida albicans</italic> bloodstream infection and sepsis</article-title>. <source>Virulence</source> (<year>2015</year>) <volume>6</volume>:<fpage>316</fpage>&#8211;<lpage>26</lpage>.<pub-id pub-id-type="doi">10.4161/21505594.2014.988096</pub-id><pub-id pub-id-type="pmid">25785541</pub-id><pub-id pub-id-type="pmcid">PMC4601378</pub-id></mixed-citation></ref><ref id="B117"><label>117</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carpino</surname><given-names>N</given-names></name><name name-style="western"><surname>Naseem</surname><given-names>S</given-names></name><name name-style="western"><surname>Frank</surname><given-names>DM</given-names></name><name name-style="western"><surname>Konopka</surname><given-names>JB</given-names></name></person-group>. <article-title>Modulating host signaling pathways to promote resistance to infection by <italic toggle="yes">Candida albicans</italic></article-title>. <source>Front Cell Infect Microbiol</source> (<year>2017</year>) <volume>7</volume>:<fpage>481</fpage>.<pub-id pub-id-type="doi">10.3389/fcimb.2017.00481</pub-id><pub-id pub-id-type="pmid">29201860</pub-id><pub-id pub-id-type="pmcid">PMC5696602</pub-id></mixed-citation></ref><ref id="B118"><label>118</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lionakis</surname><given-names>MS</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>BG</given-names></name><name name-style="western"><surname>Lim</surname><given-names>JK</given-names></name><name name-style="western"><surname>Swamydas</surname><given-names>M</given-names></name><name name-style="western"><surname>Wan</surname><given-names>W</given-names></name><name name-style="western"><surname>Richard Lee</surname><given-names>CC</given-names></name><etal/></person-group><article-title>Chemokine receptor Ccr1 drives neutrophil-mediated kidney immunopathology and mortality in invasive candidiasis</article-title>. <source>PLoS Pathog</source> (<year>2012</year>) <volume>8</volume>:<fpage>e1002865</fpage>.<pub-id pub-id-type="doi">10.1371/journal.ppat.1002865</pub-id><pub-id pub-id-type="pmid">22916017</pub-id><pub-id pub-id-type="pmcid">PMC3420964</pub-id></mixed-citation></ref><ref id="B119"><label>119</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lionakis</surname><given-names>MS</given-names></name><name name-style="western"><surname>Albert</surname><given-names>ND</given-names></name><name name-style="western"><surname>Swamydas</surname><given-names>M</given-names></name><name name-style="western"><surname>Lee</surname><given-names>CR</given-names></name><name name-style="western"><surname>Loetscher</surname><given-names>P</given-names></name><name name-style="western"><surname>Kontoyiannis</surname><given-names>DP</given-names></name></person-group>. <article-title>Pharmacological blockade of the chemokine receptor CCR1 protects mice from systemic candidiasis of hematogenous origin</article-title>. <source>Antimicrob Agents Chemother</source> (<year>2017</year>) <volume>61</volume>:<fpage>e02365-16</fpage>.<pub-id pub-id-type="doi">10.1128/AAC.02365-16</pub-id><pub-id pub-id-type="pmid">27993850</pub-id><pub-id pub-id-type="pmcid">PMC5328547</pub-id></mixed-citation></ref><ref id="B120"><label>120</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kullberg</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Arendrup</surname><given-names>MC</given-names></name></person-group><article-title>Invasive candidiasis</article-title>. <source>N Engl J Med</source> (<year>2015</year>) <volume>373</volume>:<fpage>1445</fpage>&#8211;<lpage>56</lpage>.<pub-id pub-id-type="doi">10.1056/NEJMra1315399</pub-id><pub-id pub-id-type="pmid">26444731</pub-id></mixed-citation></ref><ref id="B121"><label>121</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hung</surname><given-names>TY</given-names></name><name name-style="western"><surname>Kotecha</surname><given-names>RS</given-names></name><name name-style="western"><surname>Blyth</surname><given-names>CC</given-names></name><name name-style="western"><surname>Steed</surname><given-names>SK</given-names></name><name name-style="western"><surname>Thornton</surname><given-names>RB</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>AL</given-names></name><etal/></person-group><article-title>Immunogenicity and safety of single-dose, 13-valent pneumococcal conjugate vaccine in pediatric and adolescent oncology patients</article-title>. <source>Cancer</source> (<year>2017</year>) <volume>123</volume>:<fpage>4215</fpage>&#8211;<lpage>23</lpage>.<pub-id pub-id-type="doi">10.1002/cncr.30764</pub-id><pub-id pub-id-type="pmid">28696530</pub-id></mixed-citation></ref><ref id="B122"><label>122</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wyplosz</surname><given-names>B</given-names></name><name name-style="western"><surname>Derradji</surname><given-names>O</given-names></name><name name-style="western"><surname>Hong</surname><given-names>E</given-names></name><name name-style="western"><surname>Francois</surname><given-names>H</given-names></name><name name-style="western"><surname>Durrbach</surname><given-names>A</given-names></name><name name-style="western"><surname>Duclos-Vallee</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Low immunogenicity of quadrivalent meningococcal vaccines in solid organ transplant recipients</article-title>. <source>Transpl Infect Dis</source> (<year>2015</year>) <volume>17</volume>:<fpage>322</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1111/tid.12359</pub-id><pub-id pub-id-type="pmid">25645691</pub-id></mixed-citation></ref><ref id="B123"><label>123</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zbinden</surname><given-names>D</given-names></name><name name-style="western"><surname>Manuel</surname><given-names>O</given-names></name></person-group>. <article-title>Influenza vaccination in immunocompromised patients: efficacy and safety</article-title>. <source>Immunotherapy</source> (<year>2014</year>) <volume>6</volume>:<fpage>131</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.2217/imt.13.171</pub-id><pub-id pub-id-type="pmid">24491087</pub-id></mixed-citation></ref><ref id="B124"><label>124</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hakim</surname><given-names>H</given-names></name><name name-style="western"><surname>Allison</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Van de Velde</surname><given-names>LA</given-names></name><name name-style="western"><surname>Tang</surname><given-names>L</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Flynn</surname><given-names>PM</given-names></name><etal/></person-group><article-title>Immunogenicity and safety of high-dose trivalent inactivated influenza vaccine compared to standard-dose vaccine in children and young adults with cancer or HIV infection</article-title>. <source>Vaccine</source> (<year>2016</year>) <volume>34</volume>:<fpage>3141</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1016/j.vaccine.2016.04.053</pub-id><pub-id pub-id-type="pmid">27129426</pub-id><pub-id pub-id-type="pmcid">PMC4899146</pub-id></mixed-citation></ref><ref id="B125"><label>125</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holzmann</surname><given-names>H</given-names></name><name name-style="western"><surname>Hengel</surname><given-names>H</given-names></name><name name-style="western"><surname>Tenbusch</surname><given-names>M</given-names></name><name name-style="western"><surname>Doerr</surname><given-names>HW</given-names></name></person-group>. <article-title>Eradication of measles: remaining challenges</article-title>. <source>Med Microbiol Immunol</source> (<year>2016</year>) <volume>205</volume>:<fpage>201</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1007/s00430-016-0451-4</pub-id><pub-id pub-id-type="pmid">26935826</pub-id><pub-id pub-id-type="pmcid">PMC4866980</pub-id></mixed-citation></ref><ref id="B126"><label>126</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vickers</surname><given-names>DM</given-names></name><name name-style="western"><surname>Anonychuk</surname><given-names>AM</given-names></name><name name-style="western"><surname>De Wals</surname><given-names>P</given-names></name><name name-style="western"><surname>Demarteau</surname><given-names>N</given-names></name><name name-style="western"><surname>Bauch</surname><given-names>CT</given-names></name></person-group>. <article-title>Evaluation of serogroup C and ACWY meningococcal vaccine programs: projected impact on disease burden according to a stochastic two-strain dynamic model</article-title>. <source>Vaccine</source> (<year>2015</year>) <volume>33</volume>:<fpage>268</fpage>&#8211;<lpage>75</lpage>.<pub-id pub-id-type="doi">10.1016/j.vaccine.2013.09.034</pub-id><pub-id pub-id-type="pmid">24103896</pub-id></mixed-citation></ref><ref id="B127"><label>127</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daniels</surname><given-names>CC</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>PD</given-names></name><name name-style="western"><surname>Shelton</surname><given-names>CM</given-names></name></person-group>. <article-title>A review of pneumococcal vaccines: current polysaccharide vaccine recommendations and future protein antigens</article-title>. <source>J Pediatr Pharmacol Ther</source> (<year>2016</year>) <volume>21</volume>:<fpage>27</fpage>&#8211;<lpage>35</lpage>.<pub-id pub-id-type="doi">10.5863/1551-6776-21.1.27</pub-id><pub-id pub-id-type="pmid">26997927</pub-id><pub-id pub-id-type="pmcid">PMC4778694</pub-id></mixed-citation></ref><ref id="B128"><label>128</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moyes</surname><given-names>DL</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>D</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>JP</given-names></name><name name-style="western"><surname>Mogavero</surname><given-names>S</given-names></name><name name-style="western"><surname>Tang</surname><given-names>SX</given-names></name><name name-style="western"><surname>Wernecke</surname><given-names>J</given-names></name><etal/></person-group><article-title>Candidalysin is a fungal peptide toxin critical for mucosal infection</article-title>. <source>Nature</source> (<year>2016</year>) <volume>532</volume>:<fpage>64</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1038/nature17625</pub-id><pub-id pub-id-type="pmid">27027296</pub-id><pub-id pub-id-type="pmcid">PMC4851236</pub-id></mixed-citation></ref><ref id="B129"><label>129</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zepp</surname><given-names>F</given-names></name></person-group>. <article-title>Principles of vaccine design-lessons from nature</article-title>. <source>Vaccine</source> (<year>2010</year>) <volume>28</volume>(<issue>Suppl 3</issue>):<fpage>C14</fpage>&#8211;<lpage>24</lpage>.<pub-id pub-id-type="doi">10.1016/j.vaccine.2010.07.020</pub-id><pub-id pub-id-type="pmid">20713252</pub-id></mixed-citation></ref><ref id="B130"><label>130</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aaby</surname><given-names>P</given-names></name><name name-style="western"><surname>Roth</surname><given-names>A</given-names></name><name name-style="western"><surname>Ravn</surname><given-names>H</given-names></name><name name-style="western"><surname>Napirna</surname><given-names>BM</given-names></name><name name-style="western"><surname>Rodrigues</surname><given-names>A</given-names></name><name name-style="western"><surname>Lisse</surname><given-names>IM</given-names></name><etal/></person-group><article-title>Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period?</article-title><source>J Infect Dis</source> (<year>2011</year>) <volume>204</volume>:<fpage>245</fpage>&#8211;<lpage>52</lpage>.<pub-id pub-id-type="doi">10.1093/infdis/jir240</pub-id><pub-id pub-id-type="pmid">21673035</pub-id></mixed-citation></ref><ref id="B131"><label>131</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Biering-Sorensen</surname><given-names>S</given-names></name><name name-style="western"><surname>Aaby</surname><given-names>P</given-names></name><name name-style="western"><surname>Napirna</surname><given-names>BM</given-names></name><name name-style="western"><surname>Roth</surname><given-names>A</given-names></name><name name-style="western"><surname>Ravn</surname><given-names>H</given-names></name><name name-style="western"><surname>Rodrigues</surname><given-names>A</given-names></name><etal/></person-group><article-title>Small randomized trial among low-birth-weight children receiving bacillus Calmette-Guerin vaccination at first health center contact</article-title>. <source>Pediatr Infect Dis J</source> (<year>2012</year>) <volume>31</volume>:<fpage>306</fpage>&#8211;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1097/INF.0b013e3182458289</pub-id><pub-id pub-id-type="pmid">22189537</pub-id></mixed-citation></ref><ref id="B132"><label>132</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aaby</surname><given-names>P</given-names></name><name name-style="western"><surname>Martins</surname><given-names>CL</given-names></name><name name-style="western"><surname>Garly</surname><given-names>ML</given-names></name><name name-style="western"><surname>Bale</surname><given-names>C</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>A</given-names></name><name name-style="western"><surname>Rodrigues</surname><given-names>A</given-names></name><etal/></person-group><article-title>Non-specific effects of standard measles vaccine at 4.5 and 9 months of age on childhood mortality: randomised controlled trial</article-title>. <source>BMJ</source> (<year>2010</year>) <volume>341</volume>:<fpage>c6495</fpage>.<pub-id pub-id-type="doi">10.1136/bmj.c6495</pub-id><pub-id pub-id-type="pmid">21118875</pub-id><pub-id pub-id-type="pmcid">PMC2994348</pub-id></mixed-citation></ref><ref id="B133"><label>133</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benn</surname><given-names>CS</given-names></name><name name-style="western"><surname>Netea</surname><given-names>MG</given-names></name><name name-style="western"><surname>Selin</surname><given-names>LK</given-names></name><name name-style="western"><surname>Aaby</surname><given-names>P</given-names></name></person-group>. <article-title>A small jab&#8211;&#8211;a big effect: nonspecific immunomodulation by vaccines</article-title>. <source>Trends Immunol</source> (<year>2013</year>) <volume>34</volume>:<fpage>431</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1016/j.it.2013.04.004</pub-id><pub-id pub-id-type="pmid">23680130</pub-id></mixed-citation></ref><ref id="B134"><label>134</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kleinnijenhuis</surname><given-names>J</given-names></name><name name-style="western"><surname>Quintin</surname><given-names>J</given-names></name><name name-style="western"><surname>Preijers</surname><given-names>F</given-names></name><name name-style="western"><surname>Joosten</surname><given-names>LA</given-names></name><name name-style="western"><surname>Ifrim</surname><given-names>DC</given-names></name><name name-style="western"><surname>Saeed</surname><given-names>S</given-names></name><etal/></person-group><article-title>Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2012</year>) <volume>109</volume>:<fpage>17537</fpage>&#8211;<lpage>42</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.1202870109</pub-id><pub-id pub-id-type="pmid">22988082</pub-id><pub-id pub-id-type="pmcid">PMC3491454</pub-id></mixed-citation></ref><ref id="B135"><label>135</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kleinnijenhuis</surname><given-names>J</given-names></name><name name-style="western"><surname>Quintin</surname><given-names>J</given-names></name><name name-style="western"><surname>Preijers</surname><given-names>F</given-names></name><name name-style="western"><surname>Joosten</surname><given-names>LA</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>C</given-names></name><name name-style="western"><surname>Xavier</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>BCG-induced trained immunity in NK cells: role for non-specific protection to infection</article-title>. <source>Clin Immunol</source> (<year>2014</year>) <volume>155</volume>:<fpage>213</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1016/j.clim.2014.10.005</pub-id><pub-id pub-id-type="pmid">25451159</pub-id><pub-id pub-id-type="pmcid">PMC5084088</pub-id></mixed-citation></ref><ref id="B136"><label>136</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garcia-Valtanen</surname><given-names>P</given-names></name><name name-style="western"><surname>Guzman-Genuino</surname><given-names>RM</given-names></name><name name-style="western"><surname>Williams</surname><given-names>DL</given-names></name><name name-style="western"><surname>Hayball</surname><given-names>JD</given-names></name><name name-style="western"><surname>Diener</surname><given-names>KR</given-names></name></person-group><article-title>Evaluation of trained immunity by beta-1, 3 (d)-glucan on murine monocytes in vitro and duration of response in vivo</article-title>. <source>Immunol Cell Biol</source> (<year>2017</year>) <volume>95</volume>:<fpage>601</fpage>&#8211;<lpage>10</lpage>.<pub-id pub-id-type="doi">10.1038/icb.2017.13</pub-id><pub-id pub-id-type="pmid">28228641</pub-id><pub-id pub-id-type="pmcid">PMC5550561</pub-id></mixed-citation></ref><ref id="B137"><label>137</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leentjens</surname><given-names>J</given-names></name><name name-style="western"><surname>Quintin</surname><given-names>J</given-names></name><name name-style="western"><surname>Gerretsen</surname><given-names>J</given-names></name><name name-style="western"><surname>Kox</surname><given-names>M</given-names></name><name name-style="western"><surname>Pickkers</surname><given-names>P</given-names></name><name name-style="western"><surname>Netea</surname><given-names>MG</given-names></name></person-group>. <article-title>The effects of orally administered beta-glucan on innate immune responses in humans, a randomized open-label intervention pilot-study</article-title>. <source>PLoS One</source> (<year>2014</year>) <volume>9</volume>:<fpage>e108794</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0108794</pub-id><pub-id pub-id-type="pmid">25268806</pub-id><pub-id pub-id-type="pmcid">PMC4182605</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>